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general IntroductIon 

Introduction
1
osteoarthrItIs
Osteoarthritis (OA) is a common rheumatic disease that affects all structures of the synovial 
joint. Besides articular cartilage, the subchondral bone, synovial tissue and soft tissue 
structures around the joint may be more or less involved.1 OA may occur in any joint, 
but the spine, hands, hips, knees and feet are predilection sites.2 OA is a heterogenic, 
multifactorial disease with largely well-known systemic and biomechanical determinants 
of aetiology and progression.3-5 
history 
The early history of OA is unclear. This is mostly because of the variation in used terminology, 
due to confusion with other diseases and with generalised and secondary forms of OA.6 
From the times of Hippocrates until only 250 years ago, all forms of chronic arthritis 
were regarded as manifestations of gout. William Heberden the Elder (1710-1801) was 
the first to distinguish a form of arthritis from gout.7 He observed small nodes (that are 
nowadays named after him) without connection with gout. In 1793 Sandifort of Leiden 
described osteoarthrosis of the hip. His contemporary John Haygarth (1805) made a 
description of a polyarticular disease affecting the distal interphalangeal joints and other 
joints, perfectly resembling OA as seen in present time. Benjamin C. Brodie, professor 
of surgery in London, was one of the first to appreciate a non-inflammatory erosion of 
articular cartilage in the elderly in 1829. A few years later, Robert Smith described malum 
coxae senilis. It was distinguished from polyarticular rheumatoid arthritis by its localised 
character, probably by Robert Adams in 1831 in Dublin. Charcot and Virchow used the 
term ‘arthritis deformans’ (1869) for both OA and rheumatoid arthritis. The disease got his 
current name of ‘osteoarthritis’ in 1890 by A.E. Garrod. After the introduction of X-rays 
by Wilhelm Konrad Röntgen in 1895, Goldthwaite and others were able to distinguish 
OA from other forms of arthritis using radiographs. Kellgren and Moore linked Heberden 
nodules to OA in the early 1950s. In the next decades Kellgren and Lawrence developed 
the nowadays used radiographic grading system of OA.8 Only since a few decades OA is 
recognised as a disease that affects the whole joint, as it is nowadays. 
pathogenesis
The homeostasis of articular cartilage is driven by chondrocytes, which produce extracellular 
matrix substitutes like collagens and proteoglycans as well as the cartilage degrading 
proteinases. OA results from the failure of chondrocytes within the joint to synthesize 
a good quality matrix, in terms of resistance and elasticity, and to maintain the balance 
between synthesis and degradation of the extracellular matrix. The change in the quality 
of the extracellular matrix synthesized is due to alterations in the differentiation process 
of chondrocytes,9 via effects including alterations in expression of essential molecules on 
the chondrocytes. The imbalance between synthesis and degradation of the extracellular 
matrix is caused by increased production of proteinases. 
Although the role of the chondrocytes seems fundamental, the synovial cells are able to 
activate chondrocytes and alter the extracellular matrix of articular cartilage and therefore 
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play a prominent role in the pathogenesis of OA as well. Finally, subchondral osteoblasts 
contribute to cartilage degradation. The initiation of OA is not well-understood. It involves 
local mechanical, systemic, genetic and environmental factors.10 
epidemiology
Based on registration data from the National Public Health Compass (Nationaal Kompas 
Volksgezondheid) the point prevalence of symptomatic peripheral joint OA in The 
Netherlands is over 600,000, which makes it the third most prevalent disease after 
visual impairment and coronal disease.11 Hip and knee OA affects 29/1000 and 38/1000 
individuals, respectively, in The Netherlands. In the age-category of 60 to 64 years hip 
OA and knee OA occur in 56/1000 and 74/1000 persons, respectively. The prevalence in 
older individuals is even higher. Although OA is known to be an age-related disease, it 
is estimated that approximately 25,000 individuals aged between 25 to 44 years in The 
Netherlands have OA. 
Risk factors for OA are usually divided in risk factors for incident disease and risk 
factors for progression. The most important risk factors for incident OA include ageing, 
congenital and developmental abnormalities, joint injury, (occupational) physical activity, 
and obesity. Important risk factors for OA progression include malalignment, muscle 
weakness, and obesity.3-5 Due to demographical changes and the increase in overweight, 
an increased incidence and prevalence of OA could be expected in the near future. 
clinical aspects
Clinically OA is characterised by joint pain, stiffness, limitation of movement, crepitus and 
occasionally effusion and other signs of inflammation. The pain is generally described as 
worsening by activity and relieving by rest, whereas joint stiffness is typically present at 
initiation of movement. Generally, the symptoms due to OA vary between patients, but 
also within patients: periods of more perceived symptoms may spontaneously be followed 
by periods characterized by fewer complaints. X-rays may show joint space narrowing, 
marginal osteophytes, subchondral sclerosis and cysts. However, radiographic changes 
correlate only modestly with clinical signs.12 Therefore, the diagnosis is often made 
without abnormalities on X-rays.13-15 
management
During the last decades major advances have been made in the understanding of the 
pathogenesis of OA. Consequently, efforts are being made to develop agents with disease-
modifying properties, known as disease-modifying OA drugs (DMOADs).
Possible DMOADs, including drugs directed against cytokines involved in inflammation,16;17 
enzymes that degrade cartilage18;19 and subchondral bone20 have been investigated, mainly 
in knee OA. However, none has proven to be an irrefutable DMOAD yet.
Because interventions for OA with structure-modifying properties are not available 
at the moment, existing treatment options are directed to prevent progression and 
reduce symptoms. The most evidence-based treatment options exist for knee and hip 
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OA and comprise non-surgical and surgical interventions. The former is subdivided in non-
pharmacological and pharmacological treatments. 
Regarding non-pharmacological interventions for knee and hip OA, recommendations 
in treatment guidelines include education, lifestyle advices including regular physical 
activity, advices aiming for weight reduction in case of obesity and exercises directed 
to improvement of muscle strength and range of motion. Pharmacological treatment 
options are paracetamol (acetaminophen), (topical) non-steroidal anti-inflammatory drugs 
(NSAIDs), weak opioids and injection therapy.21-23 The use of nutritional supplements such 
as glucosamine and chondroitin is obsolete.24 
Surgical options include total joint replacement and other surgical approaches, 
like osteotomy and unicompartmental knee replacement. The role of joint lavage and 
arthroscopic debridement in knee OA is controversial.21;25 Although total knee arthroplasty 
(TKA) and  total hip arthroplasty (THA) are generally accepted as approaches to restore 
function and health-related quality of life in knee and hip OA patients, the utility is limited 
to some extent due to the frequent need for revision surgery after 10 to 15 years. Therefore, 
joint replacement is unattractive in relatively young knee and hip OA patients and joint 
replacement should in those cases be delayed as long as possible. Other drawbacks for 
joint replacement surgery are perioperative complications and persisting complaints in 10 
to 15% of patients.26  
It is generally recommended that joint replacement surgery should be reserved for 
individuals insufficiently responding to conservative treatment options.21-23 However, 
patients with knee or hip OA often have not been offered even minimum recommended 
conservative treatment.27 In addition, adherence to the widely available evidence-based 
treatment guidelines for knee and hip OA is often poor.28 Also, patients on a waiting list 
for a TKA or THA consume less health care,29 possibly indicating underuse of conservative 
treatment options.  
Due to the aforementioned drawbacks of joint replacement surgery in addition to the 
high costs of this approach and the long time patients do have OA-related symptoms until 
joint replacement, effective conservative treatment options and adherence to existing 
evidence-based treatment guidelines for knee and hip OA are essential. Moreover, the 
annual number of TKA’s and THA’s increased with 50 to 200% between 1995 and 2005 
in The Netherlands and is expected to increase further in the near future,30 indicating 
increasing incidence of OA and failure and/or underuse of conservative treatment. This 
underlines the need for optimizing conservative treatment of knee and hip OA. 
11
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 outlIne of thIs thesIs
Because effective conservative treatment is highly needed, this thesis focuses on better use 
of existing conservative treatment options in addition to studying possible new treatment 
targets in the conservative treatment of knee and hip OA. The content of the chapters in 
this thesis is outlined below.
 In Chapter 2, a study describing OA-related health care and predictors for future 
health care utilization (HCU) in a cohort of early knee and hip OA (Cohort Heup En Cohort 
Knee, Cohort Hip and Cohort Knee, CHECK31) is described. For this study, baseline and 
two-year data from the CHECK study were used.
In Chapter 3, a randomised controlled trial (RCT) of doxycycline in knee OA is 
presented. Doxycycline is one of the drugs with putative disease-modifying properties 
in OA as in one study it has shown to inhibit radiographic progression of knee OA.18 
However, the clinically important question if doxycycline exhibits symptom-modifying 
properties was not answered. Therefore, the effects of 24 weeks doxycycline on reducing 
symptoms in symptomatic knee OA were investigated. 
Although individual interventions on non-surgical management as recommended by 
the aforementioned guidelines for knee and hip OA have been shown to be effective, 
insufficient data are available on the efficacy of a combination of these interventions. In 
addition, no information is available about possible predictors for response. Therefore, a 
12-week standardised treatment protocol was developed, based on the aforementioned 
guidelines. The results of treatment according to this protocol and predictors for response 
to treatment in patients with knee and hip OA referred to secondary care are described 
in Chapter 4. 
Because there are no data on the optimal strategy regarding analgesics in the treatment 
of symptomatic knee and hip OA, a study was initiated to explore the treatment outcome 
of a numeric rating scale (NRS)-guided pharmacological pain management strategy using 
paracetamol and NSAIDs (Chapter 5). Moreover, predictors for response to paracetamol 
and NSAIDs were identified.
Besides pain, stiffness and functional decline, patients with OA frequently complain 
about fatigue. In Chapter 6, a study is described investigating the levels of fatigue in 
knee and hip OA patients, assessing change in fatigue after standardised evidence-based 
conservative treatment and studying the cross-sectional and longitudinal relationships 
between fatigue with pain and daily functioning in patients with knee or hip OA.
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predIctors of health care utIlIzatIon 
In patIents wIth early osteoarthrItIs: 
results from the check cohort
Chapter 2
aBstract
Introduction Identifying (modifiable) factors that predispose individuals with osteoarthritis 
(OA) for atypical patterns of health care utilization (HCU) (i.e. ‘persistent non-users’ or 
‘high-users’ of health care), could help health professionals to optimize a patients’ use 
of the health care system. Therefore, we aim to describe and predict HCU over time in 
individuals with early symptomatic hip and/or knee OA.
Methods Baseline and two-year data on HCU of the 1002 participants with early symptomatic 
hip and knee OA from the Cohort Hip and Cohort Knee (CHECK) study were used. Six forms 
of health care services were distinguished: use of analgesics and/or supplements, contact 
with a general practitioner, an allied health professional, secondary care or alternative care. 
By use of median split, high overall users of health care were identified. Participants without 
HCU at baseline and two years were labelled persistent non-users. Multiple imputation 
was used to handle missing data. Multivariate logistic regression was performed to identify 
predisposing, enabling and disease-related variables that could predict either high overall 
health care use at two years or persistent non-use of health care.
Results No relevant differences in HCU between participants with early hip OA (n=588) 
and participants with knee OA (n=832) were found. After two years of follow-up, contact 
with health care providers decreased in both groups, whereas use of analgesics remained 
stable. Compromised physical health and baseline use of health care were the strongest 
predictors for future high overall HCU in both the knee (Nagelkerke’s R2: 0.27) and hip 
group (Nagelkerke’s R2: 0.25). The strongest predictors for persistent non-use of health 
care were lower levels of joint stiffness and better physical health in both the knee 
(Nagelkerke’s R2: 0.23) and hip group (Nagelkerke’s R2 = 0.24).
Conclusion At two years, the majority of participants with early symptomatic hip and/or 
knee OA reported HCU for their OA complaints. To some extent future low or high-use of 
the health care system is predictable. No enabling factors were longitudinally associated 
with HCU, which suggest equity in health care for OA in The Netherlands.
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IntroductIon
Individuals with osteoarthritis (OA) often require long-term access to a broad range of 
health care services.1;2 Numerous cross-sectional studies have shown much variability in 
the amount of health care utilization (HCU) in people with OA.3-14 Moreover, a number 
of characteristics have been found to be cross-sectionally associated with higher HCU 
in people with OA, including obesity, being single, higher education, pain, disabilities, 
depression, quality of life, comorbidities and previous HCU.3;4;7-12;14
It could be of value to describe HCU over time in OA patients and identify (modifiable) 
longitudinally associated risk factors for the use of OA-related care. Understanding 
factors that predispose patients as (persistent) non-users or high-users of the health care 
system, could allow health care providers and/or policy makers to intervene and possibly 
optimize patients’ use of health care resources. To date, however, longitudinal research 
on OA related HCU is scarce15;16 and no predictors of future HCU in individuals with OA 
are available. Another hiatus in the current body of HCU evidence is the lack of studies 
describing health care consumption of individuals with early OA, whereas we believe 
patients in the earliest phase of the disease could and should be guided throughout the 
plethora of different treatment options.
According to the model of Andersen and Newman, access to health care depends 
on three types of factors: predisposing factors, enabling factors, and disease-related 
factors.17;18 Predisposing characteristics refer to demographic and social characteristics. 
Enabling resources reflect the ability to use care resources. Disease-related factors 
represent the most immediate cause for HCU, reflected by diagnosis, perception of illness, 
presence of symptoms, and disability.19 This model can be used to find evidence for 
equity or inequity in access to health care. Equity is demonstrated when care is primarily 
determined by health-related need factors and inequity is demonstrated when care is 
merely explained by enabling resources.19
The aims of this study were 1) to describe HCU and 2) to identify predictors (i.e. 
predisposing, enabling and disease-related) for future persistent non-use and high-use of 
OA-related health care services in individuals with early symptomatic hip and/or knee OA. 
To do so, we used baseline and two-year follow-up data on HCU from the Cohort Hip 
and Cohort Knee (CHECK) cohort,20 that describes participants with early symptomatic 
hip and/or knee OA.
patIents and methods
design
Baseline and two year follow-up data were used from the CHECK cohort.20 CHECK is a 
prospective cohort study of 1002 individuals with early symptomatic OA of hip and/or 
knee in The Netherlands. These individuals will be followed prospectively for a total period 
of 10 years. A total of 10 general and university hospitals are participating. Eligibility was 
checked by physicians of participating centres. Study visits for all participants were planned 
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at baseline and at two, five, eight and 10 years and consist of structured interview, physical 
examination, radiological assessment, serum- and urine-analysis, and questionnaires.
The study was approved by the medical ethics committees of all participating centres 
and all participants gave their written informed consent. Data on self-report and physical 
examination at baseline and two year data on HCU from the CHECK cohort were used for 
the current study.
study population
On entry, all participants had pain or stiffness of hip and/or knee, and were aged 
45-65 years. They had not yet consulted their physician for these symptoms, or the first 
consultation was within 6 months before entry. Participants with any other pathological 
condition that could explain the symptoms were excluded (e.g. other rheumatic disease, 
previous hip or knee joint replacement, congenital dysplasia, osteochondritis dissecans, 
intra-articular fractures, septic arthritis, Perthes’ disease, ligament or meniscus damage, 
plica syndrome, Baker’s cyst).
For our analyses, a hip group (n = 588) and a knee group (n = 832) were defined, 
based on self-reported joint pain by the participants during the first study visit. Individuals 
with both hip and knee pain were included in both groups, to reflect the typical knee and 
hip OA population.21;22
outcome measure
Health care utilization (dependent variable)
A HCU questionnaire was developed based on the one developed by Patient Panel 
Chronic Diseases (The Netherlands Institute for Health Services Research; NIVEL)23 and 
the questionnaire Economic Aspects in Rheumatoid Arthritis.24 Participants reported 
whether or not they had visited health care providers during the last three months or 
were hospitalized during the last year for their hip and/or knee problems. All available OA-
related health care services were included: the general practitioner (GP), medical specialists 
(e.g. rheumatologist, orthopaedic surgeon), allied health professionals (i.e. physiotherapy, 
occupational therapy, exercise therapy, psychology), hospital stay, use of analgesics (i.e. 
prescription and over-the-counter drugs) and/or supplements (i.e. glucosamine and/or 
chondroitin), and ‘complementary and alternative medicine’ (CAM). 
Prognostic factors (independent variables)
Patient characteristic (sociodemographic data, lifestyle factors) and comorbidity were 
collected by use of a standardised questionnaire.
Patient-reported outcome measures were determined by use of validated 
questionnaires. Pain over the last week was measured with a numeric rating scale (NRS, 
0-10).25 Condition specific health status was evaluated with the WOMAC.26;27 WOMAC 
evaluates three dimensions, pain (0-20), stiffness (0-8), and physical function (0-68), 
where higher scores represent worse health status. Self-reported health related quality 
of life was measured using the Short Form 36 (SF-36) health survey.28 The SF-36 consists 
of eighth subscales with a score range of 0-100, where 100 represents the best possible 
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health situation. The physical (PCS) and mental component summary (MCS) scores were 
calculated and fatigue and distress were assessed with the Vitality and Mental Health 
subscale of the SF-36, respectively.28 Coping behaviour was measured with the Pain 
Coping Inventory.29;30 Active coping was defined as the mean of three active strategies 
(pain transformation, distraction, and reducing demands) and passive coping as the mean 
of three passive strategy scores (retreating, worrying and resting). Value of own health 
was assessed with the visual analogue scale for health of the EuroQoL-5D questionnaire.31 
Social support was measured with the Dutch Social Support Scale.32
Physical examination of the hip consisted of measuring range of motion (internal 
rotation and flexion, in degrees) and pain (yes/no) during internal rotation and flexion. 
For the knee physical examination consisted of range of motion (flexion-extension), pain 
during flexion, bony tenderness, hydrops (refill test), crepitus, palpable warmth, and bony 
enlargement. The highest Kellgren-Lawrence Grading Scale score (range 0-4) of the two 
knees and two hips,33 was used as indicator for radiological severity.
In Box 1 all prognostic variables are depicted according to the classification of 
Andersen and Newman,17;18 namely predisposing factors, enabling factors, and disease-
related factors.
Box 1. Prognostic variables categorised according to the model of Andersen and 
Newman.
Predisposing factors
Age; Sex; BMI; Ethnicity; Marital State; Education; Family Size, Work; 
Smoking; Alcohol consumption; Coping Style (Active & Passive); Previous 
HCU.
Enabling factors
Dependency on others; Social Support; Health insurance
Disease-related factors
Comorbidity; Pain during last week; Number of painful joints (hip/knee); 
WOMAC Pain, WOMAC Stiffness, and WOMAC Physical Function; EQ-VAS; 
Distress (SF-36 Mental Health), Fatigue (SF-36 Vitality); Physical health (SF-36 
Physical Component Score); Mental health (SF-36 Mental Component Score); 
ESR.
Hip specific: Knee pain; ROM (internal rotation); ROM (Flexion); Pain during 
internal rotation; Pain during flexion; Highest K&L grade hip.
Knee specific: Hip pain; Palpable warmth; Bony tenderness; Hydrops; Bony 
enlargement; Crepitus; ROM (flexion minus extension); Pain during flexion; 
Highest K&L grade knee.
BMI body mass index; EQ-VAS EuroQol Visual Analogue Scale; ESR erythrocyte 
sedimentation rate; HCU health care utilization; K&L Kellgren and Lawrence; ROM 
Range of motion; SF-36 Short Form 36, WOMAC Western Ontario and McMasters 
University Osteoarthritis index
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statistical analysis
Statistical analyses were performed using STATA/IC 10.1 for Windows. Missing of data 
was described using descriptive analyses and missing data mechanisms were studied by 
means of indicator variables for missing values.34;35 Logistic regression models with the 
indicator variable as outcome and the other variables as covariates, showed that missing 
data was not associated to observed values, indicating that the missing values were at 
least partly missing at random (MAR) and imputation of the missing values may reduce 
bias.36 Multiple imputation using Imputation by Chained Equation (ICE) was used to 
estimate missing values.37 All available predictor variables were used for imputation. A 
total of 10 multiple imputed datasets were generated.
For all descriptive analyses, complete-case data were used. Differences in HCU between 
participants with symptomatic hip and knee OA were evaluated with chi-square tests. 
We distinguished the following six categories of health care services: 1) contact with 
GP, 2) contact with allied health professional, 3) contact in secondary care (i.e. contact 
with medical specialist and/or hospital stay), 4) use of analgesics, 5) use of supplements, 
and 6) use of CAM. In this study we aimed to identify predictors for (persistent) non-use 
of care and high-use of the health care system. To do so, we defined patients as 
persistent non-users of health care (yes/no) when they reported no utilization of any of 
the abovementioned health services both at baseline and at two years. Furthermore, we 
defined high-users of health care (yes/no) using the median split method on the number 
of health care modalities used. The median split method has been used in previous 
exploratory studies to distinct between high and low use of health care.19
Multivariable logistic regression models were built to predict persistent non-users 
and high-users of health care according to the statistical methods described by Holla 
et al.38 Independent variables were selected in five steps. Step one: the individual 
bivariate association of each independent variable with both dependent variables was 
studied by calculation of odds ratio (OR) and visual inspection of graphs plotting the 
continuous independent variables and the logit of the dependent variable. Step two: 
variables identified at step one with a p-value < 0.20 were tested for collinearity by use 
of the Variance Inflation Factor (VIF, cut-off >10) statistic.39 Step three: for each of the 
remaining variables from step two, logistic regression analyses were performed separately 
for the predefined three blocks of related factors (described above). Step four: possible 
prognostic factors identified at step three with a p-value < 0.20 were entered per block 
(i.e. predisposing, enabling and disease-related) into a backward stepwise regression 
model (p removal 0.10). Step five: the prognostic factors identified in step four were 
entered as one block into a backward stepwise regression model (p removal 0.10) to come 
to the final model.38 Multi-category dummy variables were included in the next step of the 
model building process when at least one of the set of dummy variables was significantly 
related to the outcome. Finally, ORs, Hosmer and Lemeshow goodness of fit test, Area 
Under the Receiver Operating Curve (AUC), and Nagelkerke’s R2 statistic were calculated. 
All logistic regression analyses were repeated on each of the imputed datasets, producing 
ten sets of results that were combined using Rubin’s rule of combination.40 Sensitivity 
analyses were performed on the complete case data.
22
Health care use in early osteoarthritis
2
results
study sample
Of the 1002 participants included at baseline, 982 (98%) participants completed the 
baseline questionnaire and 932 (93%) participants completed the health service 
questionnaire after two years. Of the 832 participants in the knee group, 602 (72%) had 
complete data and 750 (90%) had less than three missing values. Of the 588 participants 
in the hip group, 452 (77%) had complete data and 527 (90%) had less than three 
missing values. Knee range of motion (knee group) and erythrocyte sedimentation rate 
(ESR) (hip group) were the independent variables with the largest number of missing 
values; n=76 (9%) and n=31 (5%), respectively.
Characteristics of the study sample are presented in Table 1; for a more detailed 
description of the total population see Wesseling et al (2008).20 We found no statistical 
significant differences between the hip and knee group.
Table 1. Demographic and disease characteristics at baseline, presented for the hip and 
knee group.
Hip group Knee group
n 588 832
Age (mean (SD)) 56 (5) 56 (5)
Female 81% 80%
BMI (median (IQR)) 25 (23 – 28) 26 (24 – 28)
Married/Partnership Yes 83% 87%
No 17% 13%
Education Primary 2% 3%
Secondary 71% 71%
High professional education/
university 27% 26%
Highest K&L score 0 75% 66%
1 17% 27%
2 9% 7%
3 1% 1%
4 NA NA
WOMAC (median (IQR))
Pain (range 0 – 20) 5 (3 – 8) 5 (2 – 7)
Stiffness (range 0 – 8) 3 (2 – 4) 3 (2 – 4)
Physical function (0 – 68) 16 (8 – 25) 14 (7 – 23)
BMI body mass index; IQR interquartile range; K&L Kellgren-Lawrence Grading Scale; NA 
not available/applicable; SD standard deviation; WOMAC Western Ontario and McMaster 
Universities osteoarthritis index
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health care utilization (hcu)
Use of analgesics was the most frequently reported treatment modality at baseline (38%) 
and two years (40%) (Table 2). Contact with a GP (37%) and contact with an allied health 
care provider (20%) were the second and third most reported health care modalities 
at baseline and respectively third (13%) and second (17%) at two year follow-up. For 
almost all health care modalities a decrease or a standstill in use was observed at two 
years compared to baseline, except for the use of supplements (17% increase). Use of 
secondary care is reported by 124 (12%) participants at baseline and 71 (7%) participants 
at two years. Of these secondary care users, 35% reported no analgesics use at baseline 
nor at two years. Moreover, 44% of secondary care users reported no physical therapy use 
at baseline nor two years.
We found significant differences between the hip and knee group, for the number of 
participants that used analgesics at baseline (44% vs. 38%, respectively; p = 0.024) and 
at two years (47% vs. 41%, respectively; p = 0.019). The number of participants that had 
no HCU in two years, was significantly greater in the knee group than the hip group (50% 
vs. 43% respectively; p = 0.013).
predictors for hcu in participants with hip symptoms
A total of 237 (40%) individuals were classified as high-users of care and 102 individuals 
as persistent non-users of care (17%). Three predisposing factors and two disease-
related factors for high-use of overall health care at two-year follow-up were identified 
(Nagelkerke’s R2: 0.25) (Table 3). Risk factors for high-use of care were previous HCU 
and being widow/widower. Smoking, good physical health and greater hip flexion were 
protective factors for being a high-user of care. Strongest predictors were HCU and 
baseline and physical health.
Table 2. Health care utilization at baseline and two years for the hip and knee group.
Hip group (n=588) Knee group (n=832)
Baseline 
(T0)
(cc=577)
Two years 
(T2)
(cc=547)
Not at
T0 & T2
(cc=537)
Baseline 
(T0)
(cc=814)
Two years 
(T2)
(cc=775)
Not at 
T0 & T2
(cc=761)
Contact GP 36% 15% 58% 37% 14% 58%
Contact 
secondary care 12% 9% 80% 13% 7% 82%
Contact AHP 22% 20% 66% 19% 16% 71%
Analgesics 44%† 47%† 42% 38% 41% 48%
Glucosamine / 
Chondroitin 17% 33% 62% 15% 32% 63%
CAM 14% 11% 82% 10% 9% 86%
† = significantly different (p<0.05) from knee group. AHP allied health provider; 
CAM complementary and alternative medicine; cc complete cases; GP general practitioner
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For persistent non-use of health care four disease-related factors were identified. 
Patients with additional comorbidity and higher levels of joint stiffness were less likely to 
be persistent non-users of health care. Patients with better physical health and greater hip 
range of motion were more likely to be persistent non-users of care. Joint stiffness and 
physical health were the strongest predictors for persistent non-use of care.
predictors for hcu in participants with knee symptoms
Of the 832 individuals with early symptomatic knee OA, 291 (35%) were categorised as 
high-users of health care and 167 (20%) as persistent non-users of care. Multivariable 
logistic modelling resulted in three predisposing and five disease-related factors that 
independently predicted high overall health care use at two-years (Nagelkerke’s R2: 0.27) 
(Table 4). Risk factors for high-use of care were previous HCU, body mass index (BMI), active 
coping, additional hip pain, pain during last week, and palpable warmth. Protective factors 
were lower levels of distress and better physical health. HCU at baseline and physical health 
were found to be the strongest predictors for high-use of the health system.
For persistent non-use of health care one predisposing, one enabling and six disease-
related factors were identified (Nagelkerke’s R2: 0.23). Better physical health, better mental 
health, and greater range of knee motion were longitudinally associated with persistent 
Table 3. Baseline factors associated with high-/ non-use of HCU at 2-year in the hip group 
(n=588).
Predictor (actual range, if applicable)
High overall user
(n = 237)
Persistent non-user
(n = 102)
Health utilization, T0 (0 – 6) 1.59*** [1.35, 1.86] NA
Marital state - -
Unmarried Reference -
Married/living partnership 3.08 [0.93, 10.19] -
Widow/Widower 5.23* [1.05, 26.02] -
Divorced 2.55 [0.66, 9.81] -
Smoking 0.51* [0.28, 0.95] -
Comorbidity (0 – 4) - 0.81 [0.65, 1.01]
Stiffness (0 – 8) - 0.73*** [0.62, 0.87]
Physical Health£ (11 – 68) 0.96*** [0.94, 0.98] 1.07*** [1.04, 1.11]
Hip flexion, degrees (70 - 143) 0.98* [0.96, 0.99] 1.04** [1.01, 1.06]
AUC 0.76 [0.72, 0.80] 0.79 [0.74, 0.84]
Nagelkerke’s R2 0.25 0.24
Hosmer-Lemeshow statistic 6.51; p = 0.59 8.56; p = 0.43
Odds Ratio; 95% confidence intervals in brackets. * p < 0.05, ** p < 0.01, *** p < 0.001. 
£ = Physical Component Scale, SF-36 (range 4-71). AUC area under the receiver operating 
characteristic curve; NA not applicable; T0 baseline.
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Table 4. Baseline factors associated with high-/ non-use of HCU at 2-year in the knee 
group (n=832).
Predictor (actual range, if applicable)
High overall user
(n = 291)
Persistent non-user
(n = 167)
Health utilization, T0 (0 – 6) 1.57*** [1.37, 1.81] N/A
Body Mass Index (13 – 43) 1.05* [1.01, 1.09] -
Dependency on others - 0.35* [0.13, 0.94]
Active coping (1 – 4) 1.53* [1.04, 2.23] 0.65 [0.42, 1.00]
Hip pain 1.64** [1.17, 2.29] 0.65* [0.44, 0.97]
Pain during the last week (0 – 10) 1.10* [1.00, 1.20] -
Stiffness WOMAC (0 – 8) - 0.81** [0.71, 0.93]
Distress¥ (16 – 100) 0.99* [0.98, 1.00]
Physical health£ (11 – 69) 0.97*** [0.95, 0.99] 1.08*** [1.04, 1.11]
Mental health¶ (6 – 70) 1.04** [1.01, 1.06]
Knee ROM, degrees (58 – 155) - 1.03** [1.01, 1.06]
Hydrops - 0.49 [0.24, 1.03]
Palpable warmth 1.91 [0.99, 3.71] -
AUC 0.77 [0.73, 0.81] 0.77 [0.73, 0.81]
Nagelkerke’s R2 0.27 0.23
Hosmer-Lemeshow statistic 7.20; p = 0.53 4.30; p = 0.81
Odds Ratio; 95% confidence intervals in brackets. * p < 0.05, ** p < 0.01, *** p < 0.001. 
£ = Physical Component Scale, SF-36. ¥ = subscale Mental Health, SF-36. ¶ = Mental 
Component Scale, SF-36. AUC area under the receiver operating characteristic curve; 
N/A not applicable; ROM range of motion; T0 baseline.
non-use of care. Active coping, dependency on others, additional hip pain, higher levels 
of stiffness, and the presence of synovial effusion were longitudinally associated with not 
being a persistent non-user of health care. Physical health was found to be the strongest 
predictor for persistent non-use of the health system.
sensitivity analyses
In the knee group, complete case analyses (n=672) yielded similar prediction variables 
as the analyses on imputed data for both dependent variables, with exception of the 
following: 1) mental health and palpable warmth were no predictors for high overall use 
of care and 2) additional hip pain was and crepitus of the knee was not a predictor for 
persistent non-use of health care. 
In the hip group, complete case analyses were comparable to the imputed analyses 
for both high overall use (n=520) and persistent non-use (n=506). Exceptions being, that 
being/been in a partnership was not found to be an independent predictor for high overall 
use and ‘pain during flexion’ was an additional predictor for persistent non-use of care.
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dIscussIon
In this longitudinal study we found that the majority of participants with early symptomatic 
hip and knee OA reported health care consumption at baseline and at two years. No relevant 
differences were seen in the amount of HCU between individuals with symptomatic hip 
and knee OA. We identified several factors that were longitudinally associated with high-
use and persistent non-use of the health care system. Previous use of the health system 
and compromised physical health were the strongest predictors for future high-use of OA-
related health care. Less joint stiffness, better physical health and greater range of motion 
were the strongest predictors for persistent non-use of the health care system.
As far as we know, we are the first to identify predictors for HCU in individuals with 
early hip or knee OA. Few studies have investigated health care consumption over time in 
patients with (symptomatic) hip or knee OA.15;16 Linsell et al (2005) showed in a three-year, 
record-based follow-up study of 1410 symptomatic hip and 3152 symptomatic knee OA 
cases, that hip cases were referred to a specialist significantly more often (38 versus 32%) 
and that knee cases were more often managed using conservative treatment modalities.15 
Our results are not in line with the results of this study, as we found that individuals with hip 
complaints more frequently reported use of analgesics than patients with knee complaints. 
Moreover, we also found a much lower rate of referrals to secondary care (9% and 7% 
respectively for hip and knee). This discrepancy might be explained by differences in time 
frame of the studies, sampling methods and management of OA among different countries.
Strengths of our study include the large sample size and the fact that 10 different 
centres participated. The original response rate was very high (98%) as were retention 
rates. In addition, the amount of missing data was small. Limitations include the reliance on 
self-report data with regard to HCU which may have induced recall bias, which most likely 
resulted in overreporting.41 On the other hand, participants may have reported the contact 
with the assessor (allied health professional or clinician) as health consumption, which 
could have resulted in a slight overreporting of health care contacts. A second limitation is 
that participants in the CHECK cohort may have regarded the CHECK visits as a substitute 
for contacts with other care providers, thus possibly resulting in less utilization of health 
care. Third, the cohort is formed in The Netherlands, which affects - to some extent - the 
study’s generalisability, due to its specific health care system. In The Netherlands, GPs are 
accessible for everyone since basic health insurance is mandatory. Insurers are obligated 
to offer a package with state-controlled insured treatments and may offer additional 
optional health insurance packages at extra costs. Dutch primary care, with gatekeeping 
GPs at its core, prevents unnecessary use of more expensive secondary care, and promotes 
consistency and coordination of individual care. It is likely that the results in this study 
are particularly generalisable to countries with a similar health care system, such as the 
United Kingdom, Spain, Finland and Italy. Finally, the overlap in our findings about HCU 
in participants with hip and participants with knee symptoms could have been caused by 
the overlap in data of patients used in both the hip and knee analyses. On the other hand, 
involvement of multiple joints in the disease process of OA is very common, particularly in 
the elderly. We therefore believe that the overlap in our samples does represent the typical 
knee and hip OA population.
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Supplement use (i.e. glucosamine and chondroitin) was the only treatment modality 
that increased over the two year period. We could not find a satisfactory explanation for 
this. The CHECK cohort was formed from 2002 till 2005 and glucosamine was registered 
in The Netherlands as an over-the-counter drug in 2005, although it was available before 
that. This registration, however, hardly increased overall supplement use during that period 
in The Netherlands. Another hypothesis for this increase could be that patients try other, 
more alternative forms of care, after experiencing disappointing results from conventional 
treatments. However, this explanation is questionable since other forms of alternative care 
decreased over the two year period. Moreover, additional post-hoc analyses in our dataset 
did not support this hypothesis (data not shown). Additional long-term observation of 
supplement use in the CHECK cohort will reveal whether this is a persisting increase.
The model of Andersen and Newman is often used to find evidence for equity or 
inequity in access to health care. When care is primarily determined by health-related 
need factors, equity of care can be assumed, since patients receive the care tailored to 
their needs. When care is merely explained by enabling resources, inequity of care is 
demonstrated. In our study, the majority of prognostic factors in our prediction models 
were disease-related and to a lesser extent predisposing factors. Following the latter 
reason of deduction, we can state that there is equity in the access to health care system 
in The Netherlands for people suffering from early symptomatic OA.
An unexpected finding in our study was that smoking was a protective factor for HCU 
over time in hip pain, since smoking is generally associated with an increase in HCU.42 This 
counterintuitive, protective effect has also been reported in other areas of the disease. In 
a recent systematic review, smoking appeared to have a moderate protective effect for the 
risk of knee OA.43 However, the validity of this finding is under debate as this result was 
not apparent when restricting the analysis to cohort studies.44
In conclusion, the results of our study demonstrate that HCU remains stable over 
a period of two years and that there is equity in the access to health care services for 
patients with early symptomatic OA of the hip or knee. Previous use of the health system 
and compromised physical health were strongest predictors for future high-use of OA-
related health care. Less joint stiffness, better physical health and greater range of motion 
were the strongest predictors for persistent non-use of the health care system.
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the effects of doxycyclIne on reducIng symptoms 
In knee osteoarthrItIs: results from a 
trIple-BlInded randomIsed controlled trIal
Chapter 3
aBstract
Objectives Evidence suggests that doxycycline might have disease-modifying properties 
in osteoarthritis (OA). However, the clinically relevant question as to whether doxycycline 
also modifies symptoms in knee OA is unanswered. The objective of this study was to 
investigate the effectiveness of doxycycline on pain and daily functioning in symptomatic 
knee OA. 
Methods A 24-week, randomised, triple-blind, placebo controlled trial on the symptomatic 
effectiveness of doxycycline twice a day 100 mg in knee OA patients according to the 
clinical and radiological American College of Rheumatology (ACR) classification criteria. 
The primary endpoint was the difference in the proportion of participants in both study 
groups achieving a clinical response defined by the OMERACT-OARSI set of responder 
criteria. Secondary endpoints included pain, stiffness, daily functioning, patient global 
assessment, quality of life, OA-related medication and side effects.
Results 232 patients were randomly assigned. At study end, 31% of participants met 
the primary endpoint in both groups. Except for more adverse events in the doxycycline 
group, no differences were found on the secondary endpoints.
Conclusion Doxycycline is not effective in reducing symptoms in knee OA patients over 
a 24-week study period, but is associated with increased risk of adverse events. Although 
a possible structure-modifying effect of doxycycline was previously suggested, this is not 
accompanied by symptom relief in the short and medium term.
Dutch Trial Register number: NTR1111.
gijs f snijders1, cornelia hm van den ende1, piet lcm van riel2, frank hJ van den hoogen1 
and alfons a den Broeder1 on behalf of noac study group 
1department of rheumatology, sint maartenskliniek, nijmegen, the netherlands
2department of rheumatology, radboud university nijmegen medical centre, nijmegen, the netherlands
annals of the rheumatic diseases 2011; 70: 1191-96
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IntroductIon
The search for a disease-modifying osteoarthritis drug (DMOAD) for osteoarthritis (OA) 
targeting both symptoms and structure has been intensified in recent years. Several studies 
investigating candidate DMOADs in clinical trials have been published, including dietary 
supplements, diacerein, strontium ranalate, bisphosphonates, biologics, autologous 
conditioned serum, calcitonin and doxycycline.1-18
However, up to now, no agent is known to be an irrefutable confirmed DMOAD as 
results of most studies remain largely ambiguous or difficult to interpret. For diacerein, 
risedronate, calcitonin and autologous conditioned serum the efficacy on symptoms have 
been demonstrated in randomised controlled trials (RCTs), but these results have thus far 
not been confirmed in more than one study, except for diacerein. Effects on structural 
change have been shown for risedronate, diacerein and doxycycline,5;12;13 although these 
results have not been replicated successfully thus far.19 Whether doxycycline also modifies 
symptoms of OA has not yet been established.
Doxycycline is a tetracycline class antibiotic agent. Besides being an antimicrobial 
agent, it is a metalloproteinase inhibitor and inhibits the collagenase that cleaves collagen 
type IX that is present in the articular cartilage.20-22 Doxycycline has been studied in 
human OA in one clinical trial, in which doxycycline was found to retard progression of 
radiographic knee OA.13 The original intent of this study was to assess the efficacy of 
doxycycline to retard progression and prevent the occurrence of radiographic knee OA 
in overweight female patients with unilateral radiographic knee OA. However, although 
the contralateral knee was radiographically normal in the conventional anterior-posterior 
(AP) view, in most cases there was evidence for OA in the lateral, semiflexed AP and/
or patellofemoral view. Therefore, de facto the effect of doxycycline on the progression 
of less extensive OA in that joint was assessed. Although no effect on less extensive 
knee OA was seen, radiographic progression was substantially slower in the knee with 
established OA. No effect on pain was found, presumably due to low pain scores at 
enrolment. However, post-hoc analyses demonstrated lower incidences of increased pain 
(> 20% increase in pain score) in the index knee but not in the non-affected knee. Also, 
side effects were mild and drop-out due to possible side effects of doxycycline was rare (~ 
8%) during the 30-month trial period.
Although a proof of principle of DMOAD properties of doxycycline has thus been 
demonstrated, the clinically relevant question as to whether doxycycline also reduces pain 
and improves daily functioning in symptomatic knee OA has not been answered. 
To explore the effects of doxycycline on reducing symptoms in knee OA, a 24-week 
triple-blinded, randomised, placebo controlled trial was conducted to evaluate the effect 
of doxycycline on pain and daily functioning in well established knee OA. 
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patIents and methods
study design
This triple-blinded, randomised, placebo controlled trial was performed as a mono-centre 
study in the Sint Maartenskliniek, Nijmegen, The Netherlands. The local Medical Research 
Ethics Committee, region Arnhem/Nijmegen, The Netherlands, and the national Central 
Committee on Research involving Human Subjects (CCMO) approved the study. Moreover, 
the study was registered at EUDRACT and in the Dutch Trial Register (www.trialregister.nl; 
trial number: NTR1111). All participants gave their informed consent.
participants
Patients were eligible for inclusion if they met the following criteria: fulfilment of the 
clinical and radiological American College of Rheumatology (ACR) classification criteria 
for knee OA23 in the index knee (defined as the knee causing most complaints during the 
screening visit), Kellgren-Lawrence (K&L) score 2 or 324, Knee injury and Osteoarthritis 
Outcome Score (KOOS)-derived Western Ontario McMaster Universities (WOMAC) score 
pain subscale (see details below) of greater than 20/100 and the ability to read and 
communicate well in Dutch. Exclusion criteria were: inflammatory rheumatic diseases or 
deposition diseases possibly leading to inflammatory arthritis or secondary OA, extensive 
orthopaedic abnormalities (e.g. major malalignment (> 5°)), co-morbidity exceeding 
complaints of limitations of the knee, cognitive or sensomotor problems interfering with 
the use of questionnaires or intake of study medication, planned other major interventions 
within 24 weeks (including lower limb surgery and intensive multidisciplinary approaches), 
hip prosthesis in situ on the side of the symptomatic knee, contraindications for doxycycline 
use, such as allergy for tetracyclines and previous possible adequate treatment with 
doxycycline (> 100 mg/day for > 6 weeks for OA), recent intra-articular hyaluronic acid/
corticosteroid application or arthroscopy (< 3 months) or open surgical procedures (< 1 
year) in the index knee.
Participants were allowed to use analgesics during the study period, but they were 
asked to stop these agents during the last 48 hours and/or four times the drugs half-life 
before the study visits at the outpatient clinic (baseline, weeks 12 and 24). Opioids other 
than tramadol (up to 150 mg/day) were not allowed. 
Participants were recruited from the rheumatology and orthopaedics outpatient clinics 
and from advertisements in local newspapers.
setting
All visits and collection of data took place at the Rheumatology outpatient clinic of the 
Sint Maartenskliniek, Nijmegen, The Netherlands, a hospital specialising in rheumatology, 
orthopaedics and rehabilitation.
randomisation and intervention
Eligible patients were randomly assigned (allocation ratio 1:1) to receive either 100 mg of 
oral doxycycline monohydrate or placebo twice a day (one in the morning and one in the 
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evening) for 24 weeks. The allocation was blinded for patient and study physician (GS) 
using placebo medication capsules, blue and white, with the same appearance as verum. 
Participants who violated the study protocol were encouraged to adhere to study visits to 
limit loss to follow-up.
An independent pharmacist used a computer-generated, blinded randomisation list 
to assign patients randomly to doxycycline or placebo. Allocation data was stored at the 
hospital pharmacy in sealed envelopes that could be opened in case of medical need. To 
increase balance in possible confounders, allocation was stratified for intensity of pain 
(moderate vs. severe, i.e. < 60 vs. ≥ 60 on the WOMAC pain subscale, respectively) at the 
screening visit using stratified block randomisation. Assignment of patients to the right 
stratum of the random assignment-list was performed by the study physician (GS) who 
was blinded to therapy.
assessments
Visits were planned at screening (week -2), baseline, weeks 12 and 24 at the outpatient 
clinic and in weeks 6 and 18 by telephone. The following data were collected: 
 » Baseline characteristics: demographics, duration of complaints, previous OA-related 
treatments, concomitant medication.
 » Radiographs (at screening): bilateral (posterior-anterior fixed flexion and lateral) knee 
radiographs were performed and graded using the K&L grading scale by the study 
physician (GS).
 » Questionnaires (at screening, baseline, week 12 and week 24): to estimate knee OA-
related symptoms patients were asked to fill out the Dutch version of the Knee injury 
and Osteoarthritis Outcome Score (KOOS) (Likert-scale version) questionnaire.25 This 
questionnaire includes the Western Ontario McMaster Universities (WOMAC) score26 
in its complete and original format (with permission, http://www.koos.nu). WOMAC 
pain, stiffness and function subscales were presented as normalised scores (0 - 100, 
where 0 equals no symptoms). To assess quality of life, the Short Form-36 (SF-36)27 
questionnaire was completed by all participants. The SF-36 consists of eight subscales 
with a score range of 0 - 100, where 100 represents the best possible health situation. 
The physical (PCS) and mental component summary (MCS) scores were calculated as 
weighted means of the four physical and four mental subscale scores, respectively 
(higher scores indicate better health situation). 
 » Patient global assessment: visual analogue scale-patient global assessment (VAS-PGA), 
0 - 100, where 0 equals no symptoms (at screening, baseline, week 12 and week 24).
 » (Changes in) OA-related medication use (during all visits).
 » Adverse events: during all follow-up visits patients were asked if they experienced any 
possible adverse events, which were graded for severity. Any adverse event result-
ing in death, hospitalization, prolongation of hospitalization, or development of a 
life-threatening or debilitating condition was categorized as a Serious Adverse Event 
(SAE). Routine laboratory testing (baseline and week 24) included liver and renal func-
tion in addition to blood cell counts and vitamin B12 (the latter only at week 24).
 » Therapy adherence: pill counts (weeks 12 and 24). Adherence to therapy was defined 
as use of 80% or more of the total number of study capsules. 
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outcome
The primary endpoint was the difference in proportion of participants in both study groups 
achieving a clinical response at week 24 defined by the OMERACT-OARSI set of responder 
criteria,28 based on the WOMAC pain and function subscale scores and VAS-PGA. The 
OMERACT-OARSI criteria are defined as: (i) improvement in WOMAC pain (0 - 100) or 
WOMAC function (0 - 100) 50% or greater with an absolute change of 20 or more; or (ii) 
improvement of 20% or greater with an absolute change of 10 or more in at least two 
of the following measures: WOMAC pain, WOMAC function and VAS-PGA. Incomplete 
questionnaires at baseline were replaced by data from the screening visit (t = -2 weeks) if 
possible. In addition, incomplete questionnaires at study end (week 24) were replaced by 
data from the 12-week visit in participants who were still taking study medication at the 
end of the study (week 24). Participants who ceased study medication prematurely due to 
adverse events and were lost to follow-up were classified as non-responders. This analysis 
was done in all subjects who underwent randomisation but also pre-planned in subgroups 
with and without severe pain (intention to treat analysis).
Secondary endpoints included differences between the two study groups at week 12 
and 24 in (change in) the WOMAC subscales, VAS-PGA, MCS and PCS subscales of the 
SF-36, nature and frequency of adverse events and the (change in) use of OA-related 
medication at study end. 
sample size calculation
A difference of 20% response between the placebo and doxycycline group (number 
needed to treat 5) was considered to be clinically relevant.28 An OMERACT-OARSI response 
at 24 weeks in the placebo group of 40% was anticipated.28 Together with a requested 
power of 80%, a two-sided significance level of 0.05, an allocation ratio of 1:1 and an 
expected drop-out at week 24 of 15%, 115 patients were required per treatment arm.
statistical analysis
Statistical analyses were performed using STATA/IC 10.1 for Windows. Descriptive statistics 
were provided by using mean (SD), median (p25-p75) or frequencies/percentages depending 
on distribution of the data. All analyses were done blinded for treatment allocation.
Analysis of the primary endpoint was carried out using the intention to treat principle 
and was assessed using the Fisher’s exact test. Change scores were calculated by subtracting 
the baseline scores from the scores at weeks 12 and 24, respectively. Differences between 
both study groups in change scores of WOMAC subscales, VAS-PGA, PCS and MCS were 
analyzed using the unpaired t-test. Changes in use of OA-related medication during the 
trial were categorized in ‘more’, ‘less’ and ‘unchanged usage’ and analysed using the 
Mann-Whitney U test. The proportions of adverse events in both treatment groups were 
compared using the Fisher’s exact test. 
Additional analyses were performed regarding proportion OMERACT-OARSI responders 
in participants who completed the trial per protocol.
The imputation of missing values of data of patients lost to follow up was considered 
not appropriate as it was anticipated that loss to follow-up selectively occurred in the 
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doxycycline group due to adverse effects (missing not at random). Individuals with 
incomplete data on the primary outcome were classified as non-responders. To calculate 
change scores (secondary endpoints) only non-missing data was utilized. 
results
Between April 2008 and April 2010 232 of the 305 patients screened were enrolled and 
randomised in this study (Figure 1). Subjects in the doxycycline group reported slightly 
higher scores on WOMAC subscales and concomitant use of analgesics compared with 
the placebo group. With respect to other possible confounding variables like demographic 
variables, BMI and K&L grade both study groups were comparable at baseline. Thirty-seven 
patients had severe pain (Table 1). Among the 232 subjects who were randomised 204 
(88%) completed the trial per protocol. Significant more participants in the doxycycline 
group compared with the placebo group discontinued the study medication prematurely 
(21 versus 7, p = 0.001). Twelve participants were lost to follow-up (7 doxycycline versus 
5 placebo group). Adherence to treatment was satisfactory (i.e. ≥ 80% study capsules 
taken) in 80% of subjects who were still taking study medication at the final study visit 
(week 24) and was comparable between both study groups: 80% versus 80% in the 
doxycycline and placebo group, respectively (p = 1.0).
 
  
Excluded (n=73) 
- No informed consent: 19 
- K&L grade 4: 25 
- K&L grade 1: 16 
- Pain levels below 40/100: 5 
- Laboratory abnormalities: 4 
- Planned knee surgery within next 24 weeks: 1 
- Intra-articular injection within last 3 months: 1 
- Morphine use: 1 
- Important co-morbidity: 1 
 
Patients screened (n=305) 
Patients signed informed consent and 
randomised (n=232) 
Doxycycline (n=116) 
(intention to treat population) 
Placebo (n=116) 
(intention to treat population) 
21 dropouts 
-Adverse events (n=19) 
-Lack of efficacy (n=1) 
-Unknown (n=1) 
 7 dropouts 
-Adverse events (n=5) 
-Lack of efficacy (n=2) 
 
24 weeks 
Completed follow-up: 109 (94%) 
Completed per protocol: 95 (82%) 
24 weeks 
Completed follow-up: 111 (96%) 
Completed per protocol: 109 (94%) 
Figure 1. Study flow diagram 
Figure 1. Flow diagram
K&L grade Kellgren-Lawrence Grading Scale
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primary outcome measure
A total of 72 out of 232 (31%) participants met the OMERACT-OARSI criteria for treatment 
response at the final study visit (week 24). In the doxycycline and placebo group, 31/116 
(27%) and 41/116 (35%) met responder criteria at study end, respectively (p = 0.2). In 
participants with severe pain at week 24, nine responders were identified (2/19 in doxycycline 
group versus 7/18 in placebo group). Again, no significant difference in the proportion of 
responders was identified between the doxycycline and placebo group (p= 0.06).
secondary outcome measures
In the total study population, a significant improvement of symptoms was observed at 
week 24. Scores on the WOMAC subscales pain, stiffness, and function, and VAS-PGA 
decreased from 49 to 41 (n=218), 56 to 50 (n=215), 49 to 42 (n=210) and 52 to 44 
(n=200) respectively (all p < 0.001). Regarding quality of life, PCS improved 36 to 38 
(p<0.0001), whereas MCS showed no change (53 vs. 54, n=213, p=0.5). However, no 
differences between the two study groups were found in any measures (Table 2). 
Table 1. Baseline characteristics of patients
Variable
Total study 
population (n=232)
Doxycycline
(n=116)
Placebo 
(n=116)
Women, n (%) 154 (66) 79 (68) 75 (65)
Age (years), mean (SD) 59 (9) 59 (9) 59 (10)
BMI, mean (SD) 30 (5) 30 (6) 30 (5)
Duration of knee complaints (years), 
median (p25-75) 6 (3-15) 6 (3-14) 6 (3-15)
K&L-score = 2, number (%) 151 (65) 76 (66) 75 (65)
K&L-score = 3, number (%) 81 (35) 40 (34) 41 (35)
WOMAC score, mean (SD)
   Pain
   Function
   Stiffness
49 (18)
49 (18)
56 (21)
52 (19)
52 (18)
58 (22)
46 (17)
47 (17)
54 (19)
Severe pain, n (%) 1 37 (16) 19 (16) 18 (16)
VAS-PGA, mean (SD) 52 (25) 52 (25) 53 (26)
Pain medication use, number (%) 2
   Paracetamol
   NSAID
   Tramadol
   None
81 (35)
95 (41)
12 (5)
85 (37)
50 (43)
51 (44)
4 (3)
34 (29)
31 (27)
44 (38)
8 (7)
51 (44)
1 WOMAC pain subscale ≥ 60/100. 2 Including on-demand use.
BMI body mass index; K&L-score Kellgren-Lawrence Grading Scale; WOMAC Western 
Ontario McMaster Universities score; VAS-PGA visual analogue scale – patient global 
assessment; NSAID non-steroidal anti-inflammatory drug
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concomitant use of oa-related medication
Of the 204 participants who were still taking study medication at study end, 153 had 
unchanged, 23 had increased and 28 had decreased their OA-related medication use at 
week 24. For the doxycycline and placebo groups these numbers were: 68, 12, 15 and 85, 
11, 13, respectively, and showed no significant difference between these groups (p = 0.9).
safety
During the study, 56% of the participants reported at least one adverse event. Of the 
28 subjects who prematurely ceased study medication, 24 did so because of adverse 
events. Compared to the placebo group, significant more participants who were taking 
doxycycline ceased treatment because of side effects (19 versus five, p < 0.01). Adverse 
events in both treatment groups reported by more than two subjects are shown in Table 
3. The only adverse event which occurred significantly more often in one of the treatment 
groups was sun sensitivity. The cumulative incidence of upper respiratory tract infection 
was however somewhat lower in doxycycline treated patients, although this did not reach 
significance. Development of laboratory abnormalities was rare and did not significantly 
differ between both treatment groups. In seven subjects (five doxycycline versus two 
placebo group) low-normal vitamin B12 levels were measured at the end of the study (p = 
0.3). A total of five SAEs occurred during the trial: one traumatic patella fracture (placebo 
group), two myocardial infarction (both doxycycline group), one total knee replacement 
(doxycycline group) and one arthroscopic meniscectomy (placebo group). None of the 
SAEs were likely attributable to doxycycline, therefore no Suspected Unexpected Serious 
Adverse Reactions (SUSARs) occurred during the trial. 
sensitivity analyses
Analysis regarding the proportion of responders in subjects who completed the trial per 
protocol yielded the same results as the primary analysis. Also, analysis of (non-) response 
in adherent participants resulted in similar findings. 
dIscussIon
The findings of the present study indicate that doxycycline is not effective in reducing 
symptoms in knee OA patients over a 24-week study period, but is associated with 
increased risk of adverse events. Although previously a possible structure-modifying effect 
of doxycycline was suggested, this is not accompanied by symptom relief in the short and 
medium term. Because of the unfavourable risk-benefit ratio, doxycycline should not be 
used in the management of knee OA. 
The lack of effect seen in this study is not caused by insufficient adherence to the 
medication. Although pill counts showed that ~ 20% of the patient did not reach the target 
of taking ≥ 80% of study medication, subanalysis in adherent participants yielded the 
same findings. Although varus malalignment may have negated the symptom-modifying 
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Table 2. Secondary outcomes: improvements and differences between study groups
Outcome measure
Doxycycline Placebo
Difference
(95 % CI)n
Mean (95% 
CI) n
Mean (95% 
CI)
WOMAC pain
Baseline [SD] 116 52 [19] 115 46 [17]
Δ Week 12 - Baseline 107 -8 (-4 to -11) 110 -7 (-4 to -11) 0 (-5 to 5)
Δ Week 24 - Baseline 108 -8 (-5 to -12) 110 -8 (-3 to -12) 0 (-6 to 5)
WOMAC stiffness
Baseline [SD] 115 58 [22] 113 54 [19]
Δ Week 12 - Baseline 106 -7 (-3 to -11) 110 -9 (-5 to -13) 2 (-4 to 7)
Δ Week 24 - Baseline 108 -5 (-1 to -8) 107 -7 (-3 to -12) 3 (-3 to 8)
WOMAC function
Baseline [SD] 112 52 [18] 115 47 [17]
Δ Week 12 - Baseline 104 -7 (-4 to -10) 109 -7 (-3 to -10) -1 (-5 to 4)
Δ Week 24 - Baseline 103 -8 (-4 to -11) 107 -7 (-3 to -10) -1 (-6 to 4)
VAS-PGA
Baseline [SD] 112 52 [25] 115 53 [26]
Δ Week 12 - Baseline 100 -7 (-1 to -13) 106 -9 (-3 to -15) 1 (-7 to 10)
Δ Week 24 - Baseline 95 -7 (-1 to -13) 105 -10 (-3 to -17) 3 (-6 to 12)
PCS (possible range 4 – 71)*
Baseline [SD] 114 36 [8] 114 36 [7]
Δ Week 12 - Baseline** 104 2 (0 to 3) 109 3 (1-4) -1 (-3 to 1)
Δ Week 24 - Baseline** 105 2 (1 to 3) 108 2 (1 to 4) 0 (-2 to 3)
MCS (possible range 2 – 74)*
Baseline [SD] 114 52 [11] 114 54 [11]
Δ Week 12 - Baseline** 104 1 (-1 to 2) 109 -1 (-3 to 1) 2 (0 to 4)
Δ Week 24 - Baseline** 105 1 (-1 to 2) 108 0 (-1 to 2) 0 (-2 to 3)
Negative signs indicate improvement within groups (unless stated otherwise) or 
improvement in favour of doxycycline (in case of differences in change between groups). 
Scores are normalised (0-100; 0 = no symptoms) unless stated otherwise. * Norm-based 
scores, higher scores indicate better health, individual scores in the 45-55 range indicate 
average health. ** Negative signs indicate deterioration within groups or improvement in 
favour of placebo (in case of differences in change between groups).WOMAC Western 
Ontario McMaster Universities, PCS Physical Component Score, MCS Mental Component 
Score.
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effect of doxycycline as reported for the structure-modifying effect of doxycycline,29 this 
seems very unlikely as major malalignment was one of the exclusion criteria.
Generalisability seems to be fair as the study group is comparable with other cohorts of 
knee OA consisting mainly of middle-aged obese women.30;31 In this study a relatively low 
frequency of subjects experienced severe knee pain (16%). This is in contrast to other more 
symptomatic knee OA cohort studies, like for example the secondary care CONTROL-PRO 
cohort in which 54% of knee OA patients experience severe pain.32 However, stratified 
analyses in patients with severe pain did not show any trend for a symptom-reducing 
effect of doxycycline. Also, results of our study possibly cannot be extrapolated to knee 
OA patients with low or high radiographic K&L scores (i.e. ≤ 1 or > 3). It could be possible 
that we included participants with slightly less extensive radiographic OA compared to 
other studies, because radiographs obtained in flexion view may have a higher sensitivity 
for OA-related radiographic changes compared to conventional AP views.33 However, 
this does not challenge the validity of the present study as it does not compromises the 
external validity, because in both K&L groups a lack of response was observed indicating 
absence of effect modification.
To our knowledge, up to now no other studies have evaluated the effects of doxycycline 
on symptoms caused by OA. As mentioned earlier, the only study of doxycycline in human 
knee OA13 indicated that this agent retards radiographic progression of knee OA, although 
the primary goal of the study – reduction of progression of less extensive knee OA − was 
not met. A trend to pain reduction was also seen, possibly reflecting the anti-inflammatory 
effect of tetracyclines as studied for minocycline in RA.34
Although doxycycline (as a metalloproteinase inhibitor) does not seem to be a symptom 
modifier in the short and medium term in knee OA patients with moderate pain, this 
agent could still have potential structure-modifying effects. However, use of doxycycline 
for a longer period has some drawbacks regarding to side effects (mainly sun sensitivity) 
and possibly development of anti-microbacterial resistance. Therefore, effort has been 
made to develop synthetic metalloproteinase inhibitors,35;36 though until now without a 
favourable risk-benefit ratio.
Future research should give insight in the structure-modifying properties of inhibition 
of metalloproteinases in human OA. Regarding symptom modifying in OA, improvement of 
strategies of existing treatment modalities37 or development of new classes of analgesics38 
will probably result in better outcomes in patients with symptomatic OA.
In conclusion, present study showed that twice daily doxycycline during 24 weeks did 
not have any effect on symptoms in knee OA patients, compared to placebo. Therefore 
doxycycline should not be applied as symptom modifier in knee OA.
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aBstract
Objectives Insufficient data are available on the efficacy of combined conservative 
interventions recommended by treatment guidelines for knee and/or hip osteoarthritis 
(OA). The aims of this observational cohort study were 1) to estimate the results of an 
evidence-based 12-week tailored multimodal conservative treatment protocol for patients 
with knee and/or hip OA and 2) to identify predictors for response.
Methods After obtaining data on previous OA-related interventions, multimodal 
treatment was offered to patients with knee and/or hip OA at a specialised outpatient 
clinic. Treatment with analgesics was tailored using a numeric rating scale (NRS) for pain, 
aiming for NRS ≤ 4. The following outcome measures were assessed: 1) the proportion 
of patients fulfilling OMERACT-OARSI responder criteria and 2) the proportion of patients 
with NRS pain ≤ 4 after 12 weeks. 
Results A total of 183 out of 299 patients was included. OMERACT-OARSI responder 
criteria were fulfilled at 12 weeks in 47% of patients; 39% reached a NRS pain ≤ 4. The only 
independent predictor for response was the number of previously used non-steroidal anti-
inflammatory drugs (NSAIDs). The majority of patients had not been exposed adequately 
to conservative treatment modalities for knee and/or hip OA in the past (81%).
Conclusion Evidence-based multimodal conservative treatment using a standardised 
protocol for knee and/or hip OA is feasible and successful in 47% of patients. In general, 
response could not be predicted. Basic first-line recommended conservative treatment 
options have not been adequately utilized prior to referral to secondary care in the vast 
majority of patients.
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 IntroductIon
Recommendations in several evidence-based guidelines for knee and hip osteoarthritis 
(OA) consist of combinations of non-pharmacological and pharmacological interventions 
like information about OA, the importance of change in lifestyle, weight reduction, 
referral to a physical therapist for aerobic or strength improvement, the use of analgesics 
like paracetamol (acetaminophen) and non-steroidal anti-inflammatory drugs (NSAIDs), 
and steroid injection therapy.1-13
Although individual symptomatic interventions have been shown to be effective, 
insufficient data is available on the feasibility and efficacy of a combination of these 
interventions and possible predictors for response. Only one study investigated 
recommendations in a randomised controlled design, but unlike present study, prescription 
of analgesics was not standardised.14 
Therefore, based on the aforementioned guidelines, a 12-week standardised treatment 
protocol was developed including education, advice about weight loss and lifestyle 
measures, numeric rating scale (NRS)-tailored use of analgesics, and referral to a physical 
therapist. The protocol was implemented at a specialised outpatient clinic for conservative 
treatment of knee and hip OA. In addition, consenting patients were included in an 
observational cohort study: Cohort Of Non-invasively TReated Osteoarthritis of Lower 
extremities - Pain, function and Radiological Outcome (CONTROL-PRO) study.
The aims of this study were 1) to estimate the results of an evidence-based 12-week 
tailored multimodal conservative treatment protocol for patients with knee and/or hip OA 
and 2) to identify predictors for response.
patIents and methods
design
An observational cohort study to investigate an evidence-based standardised conservative 
treatment protocol of knee and/or hip OA was performed.
patients
All patients referred to the Rheumatology specialised outpatient clinic (‘knie/heup artrose 
poli’, knee/hip OA clinic) of the Sint Maartenskliniek, Nijmegen, The Netherlands with 
knee and/or hip OA fulfilling the clinical American College of Rheumatology (ACR) criteria 
were considered for inclusion in this observational cohort study.15;16 For knee OA the 
following criteria were used: knee pain (> 15 days of last month) plus at least three of 
the following: age > 50 years, morning stiffness < 30 minutes, crepitus, bony tenderness, 
bony enlargement or no palpable warmth. For hip OA the following criteria were used: 
hip pain (> 15 days of last month) plus internal rotation of the hip < 15° and erythrocyte 
sedimentation rate (ESR) ≤ 45 mm/hr or hip pain (> 15 days of last month) plus internal 
rotation of the hip ≥ 15° and painful internal rotation of the hip and morning stiffness ≤ 
60 minutes and age > 50 years.
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The exclusion criteria were: pain in the knee or hip on a numeric rating scale (NRS, 
0-10) of 4 or lower, inflammatory rheumatic diseases or deposition diseases possibly 
leading to inflammatory arthritis or secondary OA, severe orthopaedic abnormalities, 
co-morbidity exceeding the complaints of limitations of knee or hip OA, cognitive or 
sensomotor problems interfering with the use of questionnaires and planned orthopaedic 
procedures within the next 12 weeks. Allowed were calcium pyrophosphate deposition 
disease (CPPD; excluding the phenotypes pseudogout and polyarthritis) and previous 
meniscus problems.
Patients were asked at the first visit whether they would be willing to participate in 
the observational study (CONTROL-PRO), and if so informed consent was obtained by the 
treating physician. In patients not fulfilling inclusion and exclusion criteria or who did not 
consent, treatment was performed unaltered according to the treatment protocol.
specialised knee/hip oa outpatient clinic treatment protocol
All patients that were treated at the specialised knee/hip OA outpatient clinic received 
standardised evidence-based tailored conservative treatment in a stepped-care format as 
usual care for 12 weeks. This stepped-care model is based on a recently online published 
Dutch multidisciplinary guideline for diagnosis and treatment of knee and hip OA and 
has been proposed by a consensus panel of leading experts in the field of OA in The 
Netherlands.17;18 
The goal of the intervention was to reduce the level of pain on a NRS to 4 or lower. 
Visits were planned at week 0 and 12 at the outpatient clinic and at week 4 and 8 
by telephone and managed by a research physician (GS), a physician assistant (VS) or a 
nurse practitioner. When NRS pain remained higher than 4 and patients had taken the 
prescribed medication for at least two weeks adequately, an analgesic outlined in the next 
step of the stepped-care model was offered.
The first step of the treatment protocol consisted of education, life style advice 
concerning physical activity, weight loss advices in patients with a body mass index (BMI) 
of 28 or higher (goal: 5% weight loss in 12 weeks), referral for first-line physical therapy 
(i.e. prescription for both aerobic and strengthening exercises according to the graded 
activity principle), and treatment with paracetamol in a fixed dose of thrice a day 1000 mg 
(in case of no recent use for knee and/or hip complaints) (Figure 1). In the second step, if 
necessary and no earlier than after 4 weeks, a NSAID was added. The choice for a specific 
drug was based on previous exposure to specific NSAIDs. The preferential agent was 
naproxen, twice a day 500 mg. The third step consisted of substitution of naproxen for 
meloxicam once a day 15 mg or ibuprofen thrice a day 600 mg. The fourth step included 
the substitution of the NSAID for tramadol (thrice a day 50 mg). 
Baseline data and data on previous treatments
Baseline data were collected on demographic and disease-related characteristics using 
a standardised interview and physical examination. Data on previously used treatment 
modalities concerning knee and/or hip OA were obtained using a standardised interview 
consisting of a checklist with all common prescribed analgesics (only analgesics prescribed 
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for at least 14 consecutive days were counted; no exact dosages were required), intra-
articular injections, supplements (i.e. glucosamine and chondroitin) and physical therapy 
(minimum attendance to two sessions was required). In addition, every referred patient 
was asked to bring a list from the pharmacist or general practitioner with past prescribed 
medication to the first visit at the outpatient clinic.
radiographs
Bilateral (posterior-anterior (PA) fixed flexion and lateral) knee and pelvic radiographs were 
performed in all participants.19 Scoring of radiographs was done using Kellgren-Lawrence 
Grading Scale (K&L-score) by an experienced rheumatologist and a research physician (GS).20
numeric rating scales and questionnaires
At each visit (by telephone and at the outpatient clinic) NRS on pain and patient global 
assessment (PGA) (0-10) were administrated.
knee/hip injury and osteoarthritis outcome score (koos/hoos) and western ontario 
mcmaster universities (womac) score
At baseline and at 12 weeks, patients were asked to fill out the KOOS or HOOS (Likert-
scale version) questionnaire. These questionnaires include the WOMAC OA index in its 
complete and original format (with permission, http://www.koos.nu). WOMAC pain, 
stiffness and function subscales were calculated at baseline and after 12 weeks and 
presented as normalised scores (0-100, where 0 equals no symptoms).
Figure 1. Diagram of treatment 
protocol. When NRS remained > 
4 after 4 weeks, the next step was 
offered. 1Including weight loss if 
BMI ≥ 28 (goal: 5% reduction 
of weight in 12 weeks). 2In case 
of recent use of paracetamol: 
direct start of NSAID at first visit 
(step 2). NSAID non-steroidal 
anti-inflammatory drug; BMI 
body mass index; NRS numeric 
rating scale (0-10)
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Figure 1. Diagram of treatment protocol.  
 
 
 
When NRS remained > 4 after 4 weeks, the next step was offered. 1Including weight loss if 
BMI ≥ 28 (goal: 5% reduction of w ig t in 12 weeks). 2In case of recent use of paracetamol: 
direct start of NSAID at first visit (step 2). NSAID non-steroidal anti-inflammatory drug; 
BMI body mass index; NRS numeric rating scale (0-10) 
Education, life-style advises1, referral 
for physical therapy, prescription of 
paracetamol (acetaminophen)2  
Addition of NSAID 
Switch of NSAID 
Substitution NSAID for tramadol 
Step 1 
Step 2 
Step 3 
Step 4 
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outcome
The outcome measures included the proportion of patients after 12 weeks fulfilling 
OMERACT-OARSI criteria for response21 and the proportion of patients after 12 weeks 
with NRS pain ≤ 4.The OMERACT-OARSI criteria are defined as: 1) improvement in NRS 
pain (0-10) or WOMAC function (0-100) ≥ 50% with an absolute change ≥ 2 (NRS pain) 
or ≥ 20 (WOMAC function); or 2) improvement of ≥ 20 % with an absolute change ≥ 1 
(NRS pain) or ≥ 10 (WOMAC function) in at least two of the following measures: NRS pain, 
WOMAC function and NRS PGA. 
statistics
Since the study was observational, no formal null-hypothesis could be formulated. 
However, an exploratory sample size calculation was made as follows: to be able to 
estimate an OMERACT-OARSI response proportion of 0.4, with a confidence interval of < 
0.1, an alpha of 0.05 and a power of 0.8, a total of 154 patients were necessary. 
Patients with/without OMERACT-OARSI response after 12 weeks treatment were 
compared using the χ2-test for nominal variables and the independent t-test/Wilcoxon 
rank-sum test for continuous variables (depending on normality). To predict an OMERACT-
OARSI response, a prediction model was build. Predefined possible predictive variables 
(at baseline) were: NRS pain, NRS PGA, WOMAC function subscale, age, BMI, K&L score, 
number of previously used NSAIDs, previous use of paracetamol, surgical procedures for 
knee or hip OA and duration of knee or hip complaints. Finally, past use of key elements 
of the treatment guideline (defined as at least: paracetamol ≥ twice a day 1000 mg, at 
least one NSAID and physical therapy for knee and/or hip OA) was predefined as possible 
predictor. These variables were univariately tested first and, when an association with 
OMERACT-OARSI response was found, entered in a multivariate logistic regression analysis.
ethical considerations
The standardised treatment protocol was performed as routine clinical care in the Sint 
Maartenskliniek. The local Medical Research Ethics Committee (MREC), region Arnhem-
Nijmegen (the Netherlands) approved the study design of CONTROL-PRO (local study 
number 2009/095).
results
Between July 2007 and July 2009, 299 patients were treated according to the 
aforementioned standardised treatment protocol (Figure 2). A total of 231 patients 
fulfilled inclusion and exclusion criteria, and finally sufficient follow-up data were 
available to calculate response status after 12 weeks from 183 patients. The main reasons 
for insufficient data were lost of follow-up and incomplete questionnaires. Baseline 
characteristics are depicted in Table 1. There were no significant differences at baseline 
between patients with and without sufficient 12-week follow-up data (except a slightly 
higher NRS pain in patients without or insufficient follow-up data, 6.7 vs. 7.1 p=0.04). 
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The vast majority of patients has not been exposed adequately to conservative treatment 
modalities for knee and/or hip OA in the past (81%). After 4, 8 and 12 weeks 21%, 
30% and 39% of patients, respectively, had a NRS pain ≤ 4. OMERACT-OARSI response 
criteria were fulfilled in 86 (47%) patients after 12 weeks. Significant improvements in 
NRS pain, NRS PGA and two of three WOMAC subscales were measured at 12 weeks 
(Table 2). In the univariate analysis, NRS pain at baseline and number of NSAIDs used for 
OA were significantly associated with an OMERACT-OARSI response, with only the latter 
remaining as independent predictor for OMERACT-OARSI response after 12 weeks in the 
multivariate analyses (OR 0.77, 95% CI 0.60-0.99). Other variables were not associated 
with a treatment response (Table 3). 
dIscussIon
Our study shows that standardised tailored use of simple conservative treatment as usual 
care results in reaching of an OMERACT-OARSI response being reduced in 47% of patients 
with knee and/or hip OA. Strong independent predictors for short-term response, however, 
could not be identified except a low number of previously used NSAIDs for knee and/or 
hip OA. In addition, basic first-line recommended conservative treatment options had not 
been used adequately prior to referral to secondary care in the large majority of patients. 
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Figure 2. Study flow diagram 
 
 
Patients screened for observational study 
(n=299) 
Patients included in observational study 
(n=231) 
Not included due to not meeting inclusion  
criteria (n=60) or missing baseline data 
(n=8) 
Patients included in analyses  
(n=183) 
Not included in analyses due to insufficient  
data to calculate response status at 12  
weeks (n=48) 
Figure 2. Study flow diagram.
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Table 1. Baseline characteristics of patients (n=183) 
Variable
Women, n (%) 128 (70)
Age (years), mean (SD) 56 (10)
BMI, median (p25-75) 29 (25-32)
Knee OA, number (%) 153 (84)
Duration of knee/hip complaints (years), median (p25-75) 4 (2-9)
Disease duration (years), median (p25-75) 1 (0-3)
K&L-score ≥ 2, number (%) 109 (60)
Past treatment, number (%)
   Key elements of guidelines utilized1 
   Analgesics 
      None
      Paracetamol (acetaminophen)
      Paracetamol in adequate dose2
      One or more NSAID
      Opioids3
   Supplements4
   Physical therapy 
   Past surgical treatments for knee OA, number (%)
      One or more arthroscopies5
      Open procedures6
   Past surgical treatments for hip OA, number (%)
      One or more arthroscopies
      Open procedures
35 (19)
14 (8)
138 (75)
66 (36)
149 (81)
38 (21)
85 (47)
118 (64)
86/153 (56)
26/153 (17)
0/30
4/30 (13)
Past knee or hip trauma, number7 (%) 23 (13)
1Defined as at least: paracetamol ≥ twice a day 1000 mg (for at least 14 consecutive 
days), at least one NSAID (for at least 14 consecutive days) and physical therapy (at least 
two sessions) for knee and/or hip OA; 2Adequate dose: 2-4 times 1000mg/day during at 
least 14 consecutive days; 3Including tramadol; 4Glucosamine and chondroitin; 5Including 
partial meniscectomy; 6Including joint prosthesis; 7e.g. damage to ligaments. BMI body 
mass index; OA osteoarthritis; K&L-score Kellgren-Lawrence Grading Scale; NSAID non-
steroidal anti-inflammatory drug
Therefore, in our opinion, our findings strongly suggest that all symptomatic knee and 
hip OA patients - regardless of demographic, disease-related characteristic or previous 
treatments - should be offered conservative treatment according to existing guidelines 
first, before (partial) joint replacement is considered.
The internal validity of our study seems adequate, illustrated by ample precision. 
However, the uncontrolled design should urge caution regarding conclusions to be 
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Table 2. Results after 12 weeks
Baseline Week 12 Change 95% CI
Responder1 (%) 47 40 to 54
NRS pain (0-10) (SD) 6.7 (1) 5.3 (2) 1.4 (2) -1 to -2
NRS PGA (0-10) (SD) 6.9 (2) 5.6 (2) 1.3 (2) -0.9 to -2
WOMAC, mean (SD)2      
   pain
   stiffness
   function
57 (19)
62 (20)
58 (19)
52 (23)
58 (23)
52 (23)
-5.1 (19)
-3.8 (23)
-5.6 (19)
-2 to -8
0 to -8
-3 to -8
5% weight loss if BMI >28 at 
baseline (%), n=72 14 6 to 22
1According to OMERACT-OARSI criteria 2 Scores are normalised (0 –100; 0 = no symptoms). 
NRS numeric rating scale; WOMAC Western Ontario McMaster Universities score; BMI 
body mass index.
drawn about the effect of the intervention. Improvement of symptoms could also, at 
least partly, be explained by regression to the mean (natural history) or expectation bias 
(placebo effect). However, spontaneous regression of complaints seems to be an unlikely 
explanation because the waiting time for our outpatient clinic was approximately two to 
three months before inclusion. Moreover, all interventions integrated in the treatment 
protocol have shown symptomatic efficacy in randomised controlled trials (RCTs).10;22;22-24 
Therefore, it seems unlikely that regression to the mean would be the major contributing 
cause for the perceived effect of the intervention.
 Adherence is known to be a potent effect modifier in clinical practice. Since adherence 
was not measured routinely in this study, non-adherence to prescribed treatment modalities 
could have resulted in lower response percentages. Nevertheless, this pragmatic study was 
intended to estimate the results of the treatment protocol in daily clinical practice, thus 
including the effect of non-adherence. Therefore an intention-to-treat analysis was preferable 
over a per-protocol analysis (which perhaps would have resulted in higher response rates). 
Generalizability of the results of our study seems limited to symptomatic knee and hip 
OA patients in secondary care. In this regard, our cohort is comparable with other cohorts, 
consisting mainly of obese women with knee OA.25;26 Level of pain and BMI, however, are 
higher and patients were younger, possibly reflecting some selection as these patients are 
not ideal candidates for joint replacement after failing conservative treatment in primary 
care. Therefore, they are more likely to be referred for secondary care for conservative 
treatment. Moreover, only patients with a NRS of 4 or higher were included in this study. 
Although some additional selection could have arisen from competitive inclusion with a 
RCT regarding knee OA with mild or moderate radiographic degenerative changes during 
the inclusion period, K&L scores seem to be evenly distributed.
 In the present study, only two predictors for treatment response were identified (with 
only one remaining significant after multivariate analysis), but several possible predictors 
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that currently have not been investigated should be subject of investigation in future 
research. Among variables to be considered are serum/urine biomarkers related to 
inflammation or cartilage breakdown, specific features on (functional) imaging techniques 
or psychological factors. 
Although the finding that basic treatment modalities including paracetamol and 
physical therapy have not been adequately utilized prior to referral to secondary care 
in a substantial number of patients has been reported earlier, this is striking, bearing 
in mind that around 80% of our patients were referred to the knee/hip OA outpatient 
clinic by orthopaedic surgeons (data not shown). In most of these cases, patients were 
referred to secondary care for surgical treatment by primary healthcare workers, without 
offering adequate conservative treatment first. This finding is in concordance with studies 
on adherence to guidelines for knee OA.27;28 Notably, the point-estimates regarding past 
Table 3. Results of univariate logistic regression analysis of possible predictors (at baseline) 
for OMERACT-OARSI response at 12 weeks
Variable OR 95% CI
Gender (male) 0.60 0.31-1.14
Age 1.01 0.99-1.05
Index joint (knee) 0.71 0.32-1.58
NRS pain 0.77 0.60-0.99
NRS PGA 0.90 0.77-1.06
WOMAC function 0.99 0.98-1.01
BMI 1.03 0.98-1.09
Duration of complaints, in years 1.01 0.98-1.05
K&L-score 1.09 0.85-1.40
Past knee or hip trauma1 0.69 0.28-1.69
Key elements of guidelines utilized2 0.70 0.33-1.49
Past physical therapy for knee or hip OA 0.59 0.32-1.09
Number of NSAIDs used 0.76 0.63-0.93
Adequate use of paracetamol3 1.10 0.60-2.01
Past arthroscopies (knee OA)4 0.95 0.71-1.28
Past open surgical procedures5 0.64 0.72-3.50
1e.g. damage to ligaments; 2Defined as at least: paracetamol ≥ twice a day 1000 mg (for 
at least 14 consecutive days), at least one NSAID (for at least 14 consecutive days) and 
physical therapy (at least two sessions) for knee and/or hip OA; 3Adequate dose: 2-4 times 
1000 mg/day during at least 14 consecutive days; 4Including partial meniscectomy
5Including joint prosthesis. OR odds ratio; CI confidence interval; NRS numeric rating 
scale; PGA patient global assessment; WOMAC Western Ontario McMaster Universities 
score; BMI body mass index; K&L-score Kellgren-Lawrence Grading Scale; NSAIDs non-
steroidal anti-inflammatory drugs
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treatment modalities could be influenced by recall bias. However, recall bias might not 
be a confounder for the relation between past treatment (as a predictor) and OMERACT-
OARSI response as it is unlikely that patients who do not recall past treatments adequately 
should have a different chance to respond to the offered treatment protocol. 
The advice to reduce weight in case of obesity (with the goal being 5% reduction of 
body weight) was accomplished in 14% after 12 weeks. Although this number seems 
rather low, it is encouraging that this was solely reached by the advice to lose weight and 
referral for physical therapy. Moreover, weight reduction in combination with exercise is 
associated with improvements of self-reported measures of daily functioning and pain in 
obese older patients with knee OA.12 Nevertheless, more tailored approaches directed to 
weight reduction would be helpful, as the majority of obese patients in the present study 
did not lose weight. 
 A few questions arose that should be answered in future research. Although a short-
term response rate of 47% was reached with the described approach, the sustainability of 
these effects is so far unknown. In addition, the present results lead to the need to identify 
factors (e.g. kinesiophobia29) associated with no or minimal weight reduction, to be able 
to tailor approaches against obesity. Other important questions to be answered consider 
the ideal strategy of analgesic treatment in knee and/or hip OA. Although these agents 
are recommended in several guidelines, it is unknown whether NSAIDs should be added 
to paracetamol in the case of lack of effect, or that paracetamol should be substituted for 
a NSAID. Also, it is unknown whether the chance of response to a second or third NSAID 
is lower compared to the first NSAID, and whether (partial) opiates might be the better 
option. Furthermore, the optimal timing of and patient selection for injection therapy 
is thus far unidentified. Finally, assessing and improving adherence to therapy could be 
important approaches in the conservative treatment of knee and/or hip OA.
 In conclusion, evidence-based tailored conservative treatment using a standardised 
protocol was feasible and successful in 47% of patients, but response to treatment could 
largely not be predicted. Basic first-line recommended conservative treatment options 
have not been adequately utilized prior to referral to secondary care in the large majority 
of patients. Healthcare workers should therefore be encouraged to offer adequate 
conservative treatment, as recommended in several evidence-based treatment guidelines, 
to all patients with knee and/or hip OA.
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aBstract
Objectives To describe the results of a numeric rating scale (NRS)-guided pharmacological 
pain management strategy in symptomatic knee and/or hip osteoarthritis (OA) in daily 
clinical practice.
Methods In this observational cohort study, standardised conservative treatment was 
offered to patients with symptomatic knee and/or hip OA. Treatment with analgesics 
was tailored using a NRS for pain, aiming for NRS ≤ 4. The first step in pharmacological 
treatment was paracetamol (acetaminophen) in case of no recent use in adequate dose, 
after 4 weeks followed by NSAID 1 and subsequently after 4 weeks by a switch to NSAID 
2 in case of treatment failure. Predictors for response to treatment were identified. 
Moreover, reasons for non-adherence to the protocol were collected.
Results 347 patients were included. The proportion of patients that reached a response 
(NRS ≤ 4) after paracetamol, NSAID 1 and NSAID 2 was 25% (59 / 234), 16% (31 / 190) 
and 11% (10 / 87), respectively. Non-adherence to the protocol occurred in 46% of cases 
when switch of the analgesic was advised, mainly due to unwillingness of patients to take 
a (new) NSAID. Identified predictors for response to analgesics included higher age, lower 
patient global assessment, less stiffness and more radiographic severity. 
Conclusion Adequate use of paracetamol and switching to a NSAID after failing 
paracetamol resulted in moderate treatment response percentages, whereas the result 
of the second NSAID was disappointing in patients with advanced knee and/or hip OA. 
Predictors for response included patient and disease related factors. A substantial part of 
patients with NRS > 4 were unwilling to change their analgesics.
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IntroductIon
Recommendations in several evidence-based guidelines for knee and hip osteoarthritis 
(OA) consist of combinations of non-pharmacological, e.g. education, physical therapy 
and weight reduction, and pharmacological interventions.1-4 Because Disease Modifying 
Osteoarthritic Drugs (DMOADs) are not yet available, the most important pharmacological 
intervention is treatment with analgesics, principally using paracetamol (acetaminophen), 
non-steroidal anti-inflammatory drugs (NSAIDs) and (partial) opioids. In aforementioned 
guidelines, paracetamol is generally recommended as analgesic of first choice in the 
treatment of pain and disability related to knee or hip OA, as NSAIDs are associated with 
more side effects like gastrointestinal and cardiovascular complications.5;6 
The efficacy of paracetamol and NSAIDs in knee and hip OA has been demonstrated 
in several randomised controlled trials (RCTs).7;8 Although most studies on NSAIDs suggest 
more OA-related pain reduction than paracetamol,9;10 a few head-to-head studies indicated 
that the superiority of NSAIDs over paracetamol is questionable.11;12 Moreover, the clinical 
important questions whether prescription of a NSAID after failure of paracetamol and 
switch to another NSAID after an insufficient response to the first NSAID is warranted, 
have never been subject to research. Finally, because there is a large variation in the 
response to pain medication,13;14 it could be of value to identify predictors for response. 
In our centre, based on the aforementioned guidelines and almost similar to the 
recently developed treatment strategy on knee and hip OA in The Netherlands,15 a 
12-week standardised treatment protocol was developed consisting of a numeric rating 
scale (NRS)-guided pain management strategy (paracetamol, NSAIDs and eventually 
tramadol), in addition to education, advice about weight loss and lifestyle measures, and 
referral to a physical therapist. The protocol was implemented at a specialised outpatient 
clinic for conservative treatment of knee and hip OA.16 
The aims of present study were 1) to describe the results of a NRS-guided pain 
management strategy in symptomatic knee and hip osteoarthritis (OA) in daily clinical 
practice and 2) to identify predictors for response in daily clinical practice in symptomatic 
secondary care knee and/or hip OA.
patIents and methods
patients
All patients referred to the Rheumatology specialised outpatient clinic (‘knie/heup artrose 
poli’, knee/hip OA clinic) of the Sint Maartenskliniek with knee and/or hip OA fulfilling the 
clinical American College of Rheumatology (ACR) criteria17;18 were considered for inclusion 
in this observational cohort study. For knee OA the following criteria were used: knee pain 
(> 15 days of last month) plus at least three of the following: age > 50 years, morning 
stiffness < 30 minutes, crepitus, bony tenderness, bony enlargement or no palpable 
warmth. For hip OA the following criteria were used: hip pain (> 15 days of last month) 
plus internal rotation of the hip < 15° and erythrocyte sedimentation rate (ESR) ≤ 45 mm/
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hr or hip pain (> 15 days of last month) plus internal rotation of the hip ≥ 15° and painful 
internal rotation of the hip and morning stiffness ≤ 60 minutes and age > 50 years.
The exclusion criteria were: pain in the knee or hip on a numeric rating scale (NRS, 
0-10) of ≤ 4, inflammatory rheumatic diseases or deposition diseases possibly leading 
to inflammatory arthritis or secondary OA, co-morbidity exceeding the complaints of 
limitations of knee or hip OA, cognitive or sensomotor problems interfering with the use 
of questionnaires and planned orthopaedic procedures within the next 12 weeks. Allowed 
were calcium pyrophosphate deposition disease (CPPD) (excluding the phenotypes 
pseudogout and polyarthritis) and previous meniscus problems.
All patients were asked to participate in the CONTROL-PRO study,16 an observational 
cohort study tightly integrated with the specialised outpatient clinic.
specialised knee/hip oa outpatient clinic treatment protocol
All patients, treated at the specialised knee/hip OA outpatient clinic, received standardised 
evidence-based tailored conservative treatment in a stepped-care format as usual care for 
12 weeks. This stepped-care model is based on an online published Dutch multidisciplinary 
guideline for diagnosis and treatment of knee and hip OA and has been proposed by a 
consensus panel of leading experts in the field of OA in The Netherlands.15 
The goal of the intervention was to reduce the level of pain on a NRS to ≤ 4. Visits 
were planned at week 0 and 12 at the outpatient clinic and at week 4 and 8 by telephone 
and managed by the research physician (GS), a physician assistant or a nurse practitioner. 
When NRS pain remained higher than 4 and patients had taken the prescribed medication 
for at least two weeks adequately, the next step of the stepped-care model was offered 
(see below).
The first step of the treatment protocol consisted of education, life style advice 
concerning physical activity, weight loss advices in patients with a body mass index (BMI) 
of ≥ 28 (goal: 5% weight loss in 12 weeks), referral for first-line physical therapy (i.e. 
prescription for both aerobic and strengthening exercises according to the graded activity 
principle), and treatment with paracetamol in a fixed dose of thrice a day 1000 mg, 
in case of no recent use in adequate dose (2-4 times 1000 mg/day during at least 14 
consecutive days) for knee and/or hip complaints. (In case of recent use of paracetamol, 
treatment with a NSAID was initiated in the first step). In the second step, if necessary and 
no earlier than after 4 weeks, a NSAID (NSAID 1) was advised. The choice for a specific 
drug was based on previous exposure to specific NSAIDs. The preferential agent was 
naproxen, twice a day 500 mg. During the observation period two different polices were 
applied; before August 2009 paracetamol was continued when NSAID 1 was initiated (n 
= 44), whereas after August 2009 paracetamol was discontinued if the first NSAID was 
prescribed (n = 33). The third step consisted of substitution of naproxen for meloxicam 
once a day 15 mg or ibuprofen thrice a day 600 mg (NSAID 2). The fourth step included 
the substitution of the NSAID for tramadol (thrice a day 50 mg). 
In this study the proportion of patients responding to paracetamol, NSAID 1 and 2 
(NRS ≤ 4) were examined.
66
NRS-guided osteoarthritis pain management strategy
5
Baseline data and data on previous treatments
Baseline data were collected on demographic and disease-related characteristics using 
a standardised interview and physical examination. Data on previously used treatment 
modalities concerning knee and/or hip OA were obtained using a standardised interview 
consisting of a checklist with all common prescribed analgesics (only analgesics used for at 
least 14 consecutive days were counted; no exact dosages were required), intra-articular 
injections, supplements (i.e. glucosamine and chondroitin) and physical therapy (minimum 
attendance to two sessions was required). In addition, every referred patient was asked to 
bring a list from the pharmacist or general practitioner with past prescribed medication to 
the first visit at the outpatient clinic.
radiographs
Bilateral (posterior-anterior fixed flexion and lateral) knee and pelvic radiographs were 
performed in all participants. Scoring of radiographs was done using Kellgren-Lawrence 
Grading Scale (K&L-score)19 by an experienced rheumatologist and a research physician (GS). 
numeric rating scale (nrs) and questionnaires
At each visit the NRS pain and NRS patient global assessment (PGA) (0-10) were asked. At 
baseline, patients were asked to fill out the Knee/Hip injury and Osteoarthritis Outcome 
Score (KOOS/HOOS) (Likert-scale version) questionnaire.20;21 These questionnaires include 
the Western Ontario McMaster Universities (WOMAC)22 score index in its complete and 
original format (with permission, http://www.koos.nu). WOMAC pain, stiffness and 
function subscales were calculated at baseline and after 12 weeks and presented as 
normalised scores (0 to 100, where 0 equals no symptoms). To assess quality of life, 
the Short Form-36 (SF-36)23 questionnaire was completed by all participants. The SF-36 
consists of eight subscales with a score range of 0 to 100, where 100 represents the 
best possible health situation. The physical (PCS) and mental component summary (MCS) 
scores were calculated as weighted means of the four physical and four mental subscale 
scores, respectively (higher scores indicate better health situation).
outcome
The outcome of this study was the proportion responders (i.e. percentages patients reaching 
a NRS pain ≤ 4 after each step from the abovementioned treatment protocol), after four 
weeks use of paracetamol, after four weeks use of NSAID 1 after failing paracetamol and 
after four weeks use of NSAID 2 after failing paracetamol and NSAID 1. Previous research 
has shown that the proportion of patients fulfilling NRS pain ≤ 4 was comparable to 
the proportion OMERACT-OARSI responders24 after 12 weeks treatment according to the 
protocol (39 vs. 47 %, respectively).16 Independent predictors for response to treatment 
were identified. Furthermore, reasons for non-compliance to the study protocol were 
collected.
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statistics
Statistical analyses were performed using STATA/IC 10.1 for Windows. Descriptive 
statistics were provided by using mean (SD), median (p25-p75) or frequencies/percentages 
depending on the distribution of data. To calculate the response percentage to NSAID 1 
individuals who started the first NSAID (regardless of previous use of paracetamol) were 
taken together. Moreover, to calculate the response percentage to NSAID 2, individuals 
who started the second NSAID in the second or third step were analysed together. Around 
the proportion of responders 95%-confidence intervals (95%-CIs) were calculated. An 
exploratory sample size calculation was made as follows: to be able to estimate a response 
proportion with a 95%-CI of ≤ 0.1, an alpha of < 0.05 and a power of 0.8, 80 patients 
were necessary per group.  
To predict a treatment response (NRS pain ≤ 4 after paracetamol or first NSAID), a 
prediction model was built. Predefined candidate (baseline) predictive variables were: 
WOMAC subscales, NRS PGA, age, gender, BMI, K&L-score, index joint (knee or hip), number 
of previously used NSAIDs, previous use of paracetamol, paracetamol continued when NSAID 
was initiated (paracetamol add-on, solely to predict response to NSAID), duration of knee/
hip complaints, and MCS. These variables were first bivariately tested and, if an association 
with treatment response was found (p of removal > 0.20), entered in a multivariate logistic 
regression analysis. Using backward selection (based on p-values), the final model was built. 
For the (possible) predictors odds ratio’s (OR’s) with 95%-CI were calculated.
In individuals with incomplete data on possible predictors (i.e. WOMAC pain: n = 23, 
WOMAC stiffness: n= 81, WOMAC physical function: n=28, BMI: n=25, duration of knee/
hip complaints: n=30, NRS PGA: n=6, and MCS: n=39), single imputation was performed 
using regression modelling to replace missing values. Individuals with missing data on 
response status, i.e. missing values on NRS pain (n=32 after initiation of NSAID 1; n= 12 
after initiation of NSAID 2), were classified as non-responder.
ethical considerations
The standardised treatment protocol was performed as routine clinical care in the Sint 
Maartenskliniek. The local Medical Research Ethics Committee (MREC), region Arnhem-
Nijmegen (The Netherlands) approved the study design of CONTROL-PRO (local study 
number 2009/095). 
results
Between July 2007 and October 2010, 559 patients were treated at the specialised knee/
hip OA outpatient clinic. A total of 347 patients fulfilled inclusion and exclusion criteria 
(Figure 1). Twelve cases had insufficient data due to loss of follow-up (n = 12). Sixty 
patients were treated not in accordance to the protocol: intra-articular injections (n = 12), 
tramadol (n = 23), and NSAID combined with paracetamol (n = 25), respectively. In 30 
patients no pharmacological therapy was started at study start. Those patients were not 
included in the statistical analyses. Out of 347 patients 307 (88%) patients were referred 
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Figure 1. Study flowchart 
 
* Insufficient data: no available NRS pain at baseline or < 1 follow-up visit  
** Missing value on NRS pain 
NRS numeric rating scale; NSAID non-steroidal anti-inflammatory drug; PCM paracetamol 
(acetaminophen); pharm. pharmacological  
Start 1st NSAID 
Total n = 190 
As 1st analgesic n = 113 
As 2nd analgesic n = 77 
Excluded 
NRS pain ≤ 4: n = 110 
Different pharm. treatment: n = 60 
No pharm. treatment: n = 30 
Insufficient data: n = 12* 
Start PCM 
n = 234 
 
Missing** 
n = 16 
   
 
NRS pain > 4 
n = 159 
NRS pain ≤ 4 
n = 59 
 
Missing** 
n = 16 
   
 
NRS pain > 4 
n = 143 
NRS pain ≤ 4 
n = 31 
 
Start 2nd NSAID 
n = 87 
 
Missing** 
n = 12 
   
 
NRS pain > 4 
n = 65 
NRS pain ≤ 4 
n = 10 
 
Included 
n = 347 (NRS > 4) 
 
Total number of patients 
n = 559 
    
   
 
No 1st NSAID 
n = 82 
 
No 2nd NSAID 
n = 56 
 
Figure 1. Study flowchart. 
 In ufficient data: no available NRS pain at baseline or < 1 follow-up visit ** Missing 
value on NRS pain; NRS numeric rating scale; NSAID non-steroidal anti-inflammatory 
drug; PCM paracetamol (acetaminophen); pharm. pharmacological
to the specialised outpatient clinic by an orthopaedic surgeon, whereas the remaining 19 
(5%) and 21 (6%) patients were referred by a rheumatologist and a general practitioner, 
respectively. Baseline characteristics are depicted in Table 1. A total of 234 (67%) patients 
was treated with paracetamol in the first step. A NSAID was the pharmacological treatment 
in the first step of 113 (33%) patients (Figure 1). 
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Table 1. Baseline characteristics of patients (n= 347) 
Variable
Women, n (%) 231 (67)
Age (years), mean (SD) 55 (10)
BMI, mean (SD) 29 (5)
Knee OA, number (%) 286 (82)
Duration of knee/hip complaints (years), median (p25-75) 4 (2-10)
K&L-score ≥ 2, number (%) 226 (65)
NRS pain (0-10), mean (SD) 7 (1)
NRS patient global assessment (0-10), mean (SD) 7 (2)
WOMAC pain (0-100), mean (SD) 55 (18)
WOMAC stiffness (0-100), mean (SD) 60 (21)
WOMAC function (0-100), mean (SD) 56 (18)
MCS (possible range 2 – 74)* 50 (11)
PCS (possible range 4 – 71)* 33 (7)
Past treatment, number (%)
   Analgesics 
      None
      Paracetamol (acetaminophen)
      Paracetamol in adequate dose1
      One or more NSAID
      Opioids2
   Supplements3
   Physical therapy 
   Past surgical treatments for knee OA, number (%)
      One or more arthroscopies4
      Open procedures5
   Past surgical treatments for hip OA, number (%)
      One or more arthroscopies
      Open procedures
58 (17)
214 (62)
71 (20)
249 (72)
54 (16)
130 (37)
223 (64)
165 (58)
39 (14)
0
7 (11)
* Norm-based scores, higher scores indicate better health, individual scores in the 45-55 
range indicate average health; 1Adequate dose: 2-4 times 1000 mg/day during at least 14 
consecutive days; 2Including tramadol, 3Glucosamine and chondroitin, 4Including partial 
meniscectomy, 5Including joint prosthesis; BMI body mass index; OA osteoarthritis; K&L-
score Kellgren-Lawrence Grading Scale; NRS numeric rating scale; NSAID non-steroidal 
anti-inflammatory drug; MCS Mental Component Score of Short Form-36; PCS Physical 
Component Score of Short Form-36; WOMAC Western Ontario McMaster Universities 
Osteoarthritis Index
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outcome
Fifty-nine of the 234 patients (25%, 95%-CI 19-31) reached a NRS pain ≤ 4 after four 
weeks treatment with paracetamol. A total of 190 individuals was treated with NSAID 1 
(i.e. 77 after failing paracetamol in the first step and 113 after insufficient perceived effect 
from recent use of paracetamol prior to this study), which resulted in a response rate of 31 
/ 190 (16%, 95%-CI 10-22) patients responding. Eighty-seven patients were treated with 
NSAID 2 which resulted in 10 / 87 cases (11%, 95%-CI 4-18) in a NRS pain ≤ 4.
The following variables were bivariately associated with a response to paracetamol: 
higher age, better NRS PGA, lower WOMAC pain, lower WOMAC stiffness, lower WOMAC 
physical function, higher K&L-score, no past use of paracetamol, and low number of 
previously used NSAIDs (Table 2). Higher age, lower NRS PGA, lower WOMAC stiffness 
and higher K&L-score were independently associated with a higher chance of response to 
paracetamol (Table 4). Lower NRS PGA, lower WOMAC pain, stiffness and physical function 
were bivariately associated with a higher chance for a treatment response to NSAID 1. 
Continuing paracetamol when NSAID 1 was initiated was not associated with response to 
NSAID 1 (Table 3). However, only lower NRS PGA was identified as independent predictor 
for a response to NSAID 1 (Table 4). The index joint (knee or hip) was not associated with 
response to paracetamol or NSAIDs. 
Table 2. Results of univariate logistic regression analysis of possible predictors (at baseline) 
for treatment response to paracetamol (n= 234)
Variable OR 95% CI
Gender (male) 1.10 0.61 – 2.01
Age 1.04 1.01 – 1.07
Index joint (knee) 1.87 0.91 – 3.82
NRS PGA 0.80 0.67 – 0.95
WOMAC pain 0.98 0.96 – 1.00
WOMAC stiffness 0.98 0.97 – 1.00
WOMAC physical function 0.98 0.96 – 0.99
BMI 0.98 0.93 – 1.00
Duration of complaints, in years 0.99 0.93 – 1.04
K&L-score 1.47 1.13 – 1.91
Previous use of paracetamol (yes) 0.51 0.28 – 0.94
Number of previously used NSAIDs 0.74 0.56 – 0.97
MCS 0.99 0.96 – 1.01
OR odds ratio; CI confidence interval; NRS numeric rating scale; PGA patient global 
assessment; WOMAC Western Ontario McMaster Universities score; BMI body mass index; 
K&L-score Kellgren-Lawrence Grading Scale; NSAIDs non-steroidal anti-inflammatory 
drugs; MCS Mental Component Score of Short Form-36
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Table 3. Results of univariate logistic regression analysis of possible predictors (at baseline) 
for treatment response to NSAID 1 (n= 190)
Variable OR 95% CI
Gender (male) 0.92 0.39 – 2.14
Age 1.02 0.96 – 1.06
Index joint (knee) 0.90 0.32 – 2.55
NRS PGA 0.71 0.56 – 0.89
WOMAC pain 0.97 0.95 – 0.99
WOMAC stiffness 0.98 0.96 – 1.00
WOMAC physical function 0.97 0.95 – 1.00
BMI 1.04 0.97 – 1.11
Duration of complaints, in years 1.03 0.99 – 1.06
K&L-score 1.39 0.98 – 1.97
Previous use of paracetamol (yes) 1.34 0.37 – 4.83
Paracetamol add on* (yes) 1.45 0.61 – 3.43
Number of previously used NSAIDs 0.75 0.57 – 1.00
MCS 1.03 0.99 – 1.07
* In the first 44 patients with no response to paracetamol as first step of the protocol, 
paracetamol was continued when first NSAID 1 was started at the second step 
OR odds ratio; CI confidence interval; NRS numeric rating scale; PGA patient global 
assessment; WOMAC Western Ontario McMaster Universities score; BMI body mass index; 
K&L-score Kellgren-Lawrence Grading Scale; NSAIDs non-steroidal anti-inflammatory 
drugs; MCS Mental Component Score of Short Form-36
non-adherence to protocol
A total of 138 out of 302 (46%) patients did not start with a (new) NSAID after failing 
paracetamol or the first NSAID (i.e. persistent NRS > 4) (Figure 1). Reasons for these 
protocol-violations were: pain-level acceptable 17 / 138 (12%) and unwillingness to take 
a NSAID 53 / 138 (39%). In 39 out of 138 cases (28%) no reason for the protocol-violation 
could be identified, possibly reflecting inadequately offering the next step of the protocol 
by the caregiver. Other reasons for no switch to a (new) NSAID were: contra-indication (10 
/ 138, 7%) and start of different pharmacological treatment (19 / 138, 14%).
dIscussIon
This is the first study analysing a NRS-guided pain management strategy in daily knee and 
hip OA care. Our study shows that NRS-tailored use of paracetamol results in a response 
percentage of 25% and that treatment with a NSAID after failing paracetamol leads to a 
treatment response of 16% in secondary care knee and hip OA patients. Treatment with 
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a second NSAID after failing paracetamol and the first NSAID resulted only occasionally in 
a treatment response (i.e. 11%). We therefore conclude that prescription of paracetamol 
and prescription of a NSAID after insufficient results with paracetamol are of value in 
knee and/or hip OA patients referred to secondary care, even after considering joint 
replacement. Some predictors for response to paracetamol and a NSAID were identified - 
including patient- and disease related factors - however, no strong predictors were found.
The percentage protocol violations, i.e. no switch of analgesic or switch to an agent 
not according to the protocol, was 46%. This proportion is comparable with data from a 
post-hoc analysis in a RCT in rheumatoid arthritis in which rheumatologists were advised 
about the right methotrexate dose according to the protocol before each visit, but were 
allowed to deviate from the protocol.25 In 51% of these protocol violations no medication 
switch - although appropriate according to the protocol - was performed because patients 
perceived their pain level as acceptable and/or were unwilling to try a (new) NSAID. 
Possibly, these results reflect fear for adverse events of NSAIDs and the individual variation 
in the patient acceptable symptom state (PASS). The mean PASS for pain lies below 4 (32 
mm (95%-CI 30-35) for knee OA and 35 mm (95%-CI 33-37) for hip OA on a 100 mm 
visual analogue scale), but our study indicates that a considerable proportion of patients 
reports a PASS beyond 4.26 
The internal validity of our study seems adequate, illustrated by ample precision. 
However, the uncontrolled design should urge to caution regarding conclusions to be 
drawn about the effect of the interventions. Improvement of symptoms could also, at 
least partly, be explained by regression to the mean (natural history) or expectation bias 
(placebo effect). However, spontaneous regression of complaints seems to be an unlikely 
explanation because the waiting time for our outpatient clinic was approximately two to 
Table 4. Prediction models with independently predictors for response to paracetamol 
(n= 234) and first NSAID (n = 190)
Variable OR 95% CI
Response to paracetamol
Age 1.03 1.00 – 1.07
NRS PGA 0.80 0.66 – 0.97
WOMAC stiffness 0.98 0.96 – 0.99
K&L-score 1.43 1.07 – 1.92
R2 = 0.11; AUC 0.74
Response to first NSAID 
NRS PGA 0.71 0.56 – 0.89
R2 = 0.05; AUC 0.66
OR odds ratio; CI confidence interval; NRS numeric rating scale; PGA patient global 
assessment; WOMAC Western Ontario McMaster Universities score; K&L-score 
Kellgren-Lawrence Grading Scale; AUC area under the curve NSAIDs non-steroidal anti-
inflammatory drugs
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three months before inclusion. Also, the response percentages found in this study seem 
comparable to the differences between the intervention and placebo arm in analgesic 
trials,27 and improvement was rarely seen after the second NSAID. Therefore, we conclude 
that the occurrence of type I errors is unlikely.
 The response percentages with paracetamol could be inflated by effects of the other 
treatment modalities offered during the baseline visit. However, the effects of physical 
therapy are not to be expected within the first 4 weeks as there was usually a waiting list 
of a few weeks before attendance. 
 Adherence to prescribed medication is known to be a potent effect modifier in clinical 
practice. Since adherence to prescribed treatment was not routinely measured in this study, 
non-adherence to prescribed treatment modalities could have resulted in lower response 
percentages. Nevertheless, this pragmatic study was intended to estimate and compare 
the results of paracetamol and NSAIDs in addition to non-pharmacological interventions 
in daily clinical practice, thus including the effects of non-adherence.
Generalizability of the results of our study seems limited to symptomatic knee and hip 
OA patients in secondary care. In this light, our cohort is comparable with other cohorts, 
consisting mainly of obese women with knee OA.28;29 Level of pain and BMI, however, are 
higher and patients were younger, possibly reflecting some selection as the vast majority of 
patients was referred by orthopaedic surgeons mostly because of absence of an indication 
for joint replacement surgery. Also, relatively high rates of surgical procedures in the past 
(in the knee OA group) exist in current study.
Predicting a treatment response to pharmacological interventions with pre-treatment 
variables could be valuable as it could result in prevention of unnecessary exposure to 
potentially toxic agents. However, we were unable to identify strong independent 
predictors for response to paracetamol or NSAIDs. Higher K&L-scores as predictor for 
response to paracetamol has never reported before, though it is an additional argument 
to try paracetamol before considering joint replacement even in advanced knee and hip 
OA. In a recently published study on predictors of response to cyclo-oxygenase-2 (COX-2) 
inhibitors, the only consistent predictor for an OMERACT-OARSI response was WOMAC 
physical function.30 Other studies report various, but no consistent predictors for treatment 
response to NSAIDs.31;32 Possibly, the response to pharmacological agents is determined by 
other non-measured variables. 
Future research should be focussed on improvement of the pharmacological treatment 
strategy of symptomatic knee and hip OA, e.g. the place of (partial) opioids, paracetamol 
combined with a NSAID and intra-articular injections combined with analgesics. 
Furthermore, the ideal treatment strategy could possibly be improved with shortening 
the trial period of a pharmacological agent, as the response after two weeks treatment 
with COX-2 inhibitors in two randomised controlled trials was a strong predictor of 
OMERACT-OARSI response at 12-weeks treatment.33 Another study showed similar results 
for paracetamol.34 Also, n of 1 trials could be used to discover the best treatment for 
an individual person, in which patients are exposed to different analgesics during short 
trial periods.35 Finally, development of novel classes symptom reducing agents should be 
encouraged, although precaution of side effects is warranted.36
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 In conclusion, protocolised prescription of paracetamol and a NSAID after failing 
paracetamol resulted in moderate treatment response percentages, whereas the results 
of switching between NSAIDs were disappointing in secondary care knee and hip OA 
patients in daily clinical practice. Response to paracetamol or a NSAID could largely not 
be predicted. We therefore conclude that prescription of paracetamol, and prescription of 
a NSAID after insufficient results with paracetamol, is appropriate in patients with severe 
knee or hip OA, even after prior consideration for joint replacement. Reasons for non-
compliance to initiation of analgesics should be further investigated. 
75
Chapter 5
reference lIst
1. Jordan KM, Arden NK, Doherty M et 
al. EULAR Recommendations 2003: 
an evidence based approach to the 
management of knee osteoarthritis: Report 
of a Task Force of the Standing Committee 
for International Clinical Studies Including 
Therapeutic Trials (ESCISIT). Ann.Rheum.
Dis. 2003; 62: 1145-55.
2. Zhang W, Doherty M, Arden N et al. EULAR 
evidence based recommendations for the 
management of hip osteoarthritis: report 
of a task force of the EULAR Standing 
Committee for International Clinical Studies 
Including Therapeutics (ESCISIT). Ann.
Rheum.Dis. 2005; 64: 669-81.
3. Recommendations for the medical 
management of osteoarthritis of the hip 
and knee: 2000 update. American College 
of Rheumatology Subcommittee on 
Osteoarthritis Guidelines. Arthritis Rheum. 
2000; 43: 1905-15.
4. Zhang W, Moskowitz RW, Nuki G et al. OARSI 
recommendations for the management 
of hip and knee osteoarthritis, Part II: 
OARSI evidence-based, expert consensus 
guidelines. Osteoarthritis.Cartilage. 2008; 
16: 137-62.
5. Hernandez-Diaz S, Rodriguez LA. 
Association between nonsteroidal 
anti-inflammatory drugs and upper 
gastrointestinal tract bleeding/perforation: 
an overview of epidemiologic studies 
published in the 1990s. Arch.Intern.Med. 
2000; 160: 2093-9.
6. McGettigan P, Henry D. Cardiovascular 
risk and inhibition of cyclooxygenase: a 
systematic review of the observational 
studies of selective and nonselective 
inhibitors of cyclooxygenase 2. JAMA 2006; 
296: 1633-44.
7. Bjordal JM, Ljunggren AE, Klovning A et 
al. Non-steroidal anti-inflammatory drugs, 
including cyclo-oxygenase-2 inhibitors, in 
osteoarthritic knee pain: meta-analysis of 
randomised placebo controlled trials. BMJ 
2004; 329: 1317.
8. Towheed TE, Maxwell L, Judd MG et 
al. Acetaminophen for osteoarthritis. 
Cochrane.Database.Syst.Rev. 2006; 
CD004257.
9. Zhang W, Jones A, Doherty M. Does 
paracetamol (acetaminophen) reduce the 
pain of osteoarthritis? A meta-analysis of 
randomised controlled trials. Ann.Rheum.
Dis. 2004; 63: 901-7.
10. Pincus T, Koch GG, Sokka T et al. A 
randomized, double-blind, crossover 
clinical trial of diclofenac plus misoprostol 
versus acetaminophen in patients with 
osteoarthritis of the hip or knee. Arthritis 
Rheum. 2001; 44: 1587-98.
11. Williams HJ, Ward JR, Egger MJ et 
al. Comparison of naproxen and 
acetaminophen in a two-year study of 
treatment of osteoarthritis of the knee. 
Arthritis Rheum. 1993; 36: 1196-206.
12. Bradley JD, Brandt KD, Katz BP et al. 
Comparison of an antiinflammatory dose of 
ibuprofen, an analgesic dose of ibuprofen, 
and acetaminophen in the treatment of 
patients with osteoarthritis of the knee. 
N.Engl.J.Med. 1991; 325: 87-91.
13. Huskisson EC, Woolf DL, Balme HW et 
al. Four new anti-inflammatory drugs: 
responses and variations. Br.Med.J. 1976; 
1: 1048-9.
14. Pavelka K, Peliskova Z, Stehlikova H et al. 
Intraindividual differences in pain relief and 
functional improvement in osteoarthritis 
with diclofenac or tramadol. Clin.Drug 
Investig. 1998; 16: 421-9.
15. van den Ende CM, Bierma-Zeinstra SM, Vliet 
Vlieland TP et al. [Conservative treatment of 
hip and knee osteoarthritis: a systematic, 
step-by-step treatment strategy]. Ned 
Tijdschr Geneeskd. 2010; 154: A1574.
16. Snijders GF, den Broeder AA, van Riel PL 
et al. Evidence-based tailored conservative 
treatment of knee and hip osteoarthritis: 
between knowing and doing. 
Scand.J.Rheumatol. 2011; 40: 225-31.
17. Altman R, Alarcon G, Appelrouth D et al. 
The American College of Rheumatology 
criteria for the classification and reporting 
of osteoarthritis of the hip. Arthritis Rheum. 
1991; 34: 505-14.
18. Altman R, Asch E, Bloch D et al. Development 
of criteria for the classification and 
reporting of osteoarthritis. Classification 
of osteoarthritis of the knee. Diagnostic 
and Therapeutic Criteria Committee of 
the American Rheumatism Association. 
Arthritis Rheum. 1986; 29: 1039-49.
19. Kellgren JH, Lawrence JS. Radiological 
assessment of osteo-arthrosis. Ann.Rheum.
Dis. 1957; 16: 494-502.
20. de Groot I, Favejee MM, Reijman M et al. 
The Dutch version of the Knee Injury and 
Osteoarthritis Outcome Score: a validation 
76
NRS-guided osteoarthritis pain management strategy
5
study. Health Qual.Life Outcomes. 2008; 6: 
16.
21. de Groot I, Reijman M, Terwee CB et al. 
Validation of the Dutch version of the Hip 
disability and Osteoarthritis Outcome Score. 
Osteoarthritis.Cartilage. 2007; 15: 104-9.
22. Bellamy N, Buchanan WW, Goldsmith CH 
et al. Validation study of WOMAC: a health 
status instrument for measuring clinically 
important patient relevant outcomes to 
antirheumatic drug therapy in patients 
with osteoarthritis of the hip or knee. 
J.Rheumatol. 1988; 15: 1833-40.
23. Ware JE, Jr., Sherbourne CD. The MOS 
36-item short-form health survey (SF-36). I. 
Conceptual framework and item selection. 
Med.Care 1992; 30: 473-83.
24. Pham T, van der Heijde D, Altman RD et al. 
OMERACT-OARSI initiative: Osteoarthritis 
Research Society International set of 
responder criteria for osteoarthritis clinical 
trials revisited. Osteoarthritis.Cartilage. 
2004; 12: 389-99.
25. Fransen J, Laan RF, van der Laar MA et 
al. Influence of guideline adherence on 
outcome in a randomised controlled trial 
on the efficacy of methotrexate with folate 
supplementation in rheumatoid arthritis. 
Ann.Rheum.Dis. 2004; 63: 1222-6.
26. Tubach F, Ravaud P, Baron G et al. Evaluation 
of clinically relevant states in patient reported 
outcomes in knee and hip osteoarthritis: the 
patient acceptable symptom state. Ann.
Rheum.Dis. 2005; 64: 34-7.
27. Clegg DO, Reda DJ, Harris CL et al. 
Glucosamine, chondroitin sulfate, and 
the two in combination for painful knee 
osteoarthritis. N.Engl.J.Med. 2006; 354: 
795-808.
28. Wesseling J, Dekker J, van den Berg WB 
et al. CHECK (Cohort Hip and Cohort 
Knee): similarities and differences with the 
Osteoarthritis Initiative. Ann.Rheum.Dis. 
2009; 68: 1413-9.
29. van Dijk GM, Veenhof C, Spreeuwenberg P 
et al. Prognosis of limitations in activities in 
osteoarthritis of the hip or knee: a 3-year 
cohort study. Arch.Phys.Med.Rehabil. 
2010; 91: 58-66.
30. Bingham Iii CO, Smugar SS, Wang H 
et al. Predictors of Response to Cyclo-
Oxygenase-2 Inhibitors in Osteoarthritis: 
Pooled Results from Two Identical Trials 
Comparing Etoricoxib, Celecoxib, and 
Placebo. Pain Med. 2011.
31. Detora LM, Krupa D, Bolognese J et al. 
Rofecoxib shows consistent efficacy in 
osteoarthritis clinical trials, regardless of 
specific patient demographic and disease 
factors. J.Rheumatol. 2001; 28: 2494-503.
32. Walker JS, Sheather-Reid RB, Carmody JJ 
et al. Nonsteroidal antiinflammatory drugs 
in rheumatoid arthritis and osteoarthritis: 
support for the concept of “responders” 
and “nonresponders”. Arthritis Rheum. 
1997; 40: 1944-54.
33. Bingham CO, III, Smugar SS, Wang H et 
al. Early response to COX-2 inhibitors 
as a predictor of overall response in 
osteoarthritis: pooled results from two 
identical trials comparing etoricoxib, 
celecoxib and placebo. Rheumatology 
(Oxford) 2009; 48: 1122-7.
34. Battisti WP, Katz NP, Weaver AL et al. Pain 
management in osteoarthritis: a focus 
on onset of efficacy--a comparison of 
rofecoxib, celecoxib, acetaminophen, and 
nabumetone across four clinical trials. J.Pain 
2004; 5: 511-20.
35. Wegman AC, van der Windt DA, de 
Haan M et al. Switching from NSAIDs to 
paracetamol: a series of n of 1 trials for 
individual patients with osteoarthritis. Ann.
Rheum.Dis. 2003; 62: 1156-61.
36. Lane NE, Schnitzer TJ, Birbara CA et al. 
Tanezumab for the treatment of pain from 
osteoarthritis of the knee. N.Engl.J.Med. 
2010; 363: 1521-31.
77
6
fatIgue In knee and hIp osteoarthrItIs: 
the role of paIn and physIcal functIon
Chapter 6
gijs f snijders1, cornelia hm van den ende1, Jaap fransen2, piet lcm van riel2, mirelle Jpm 
stukstette1, koen c defoort3, marianne a arts-sanders1, frank hJ van den hoogen1 and alfons 
a den Broeder1 on behalf of noac study group 
1department of rheumatology, sint maartenskliniek, nijmegen, the netherlands
2department of rheumatology, radboud university nijmegen medical centre, nijmegen, the netherlands
3department of orthopaedics, sint maartenskliniek, nijmegen, the netherlands
rheumatology (oxford) 2011 E-pub ahead of print
aBstract
Objectives It is suggested that serious levels of fatigue are present in nearly half of 
patients with osteoarthritis (OA). However, it is unclear which dimensions of fatigue are 
involved, if fatigue is related to pain and daily functioning, and if fatigue is influenced by 
therapy. The aims of this study were to measure levels of different dimensions of fatigue 
before and after evidence-based conservative treatment and to investigate the association 
between fatigue and pain and physical function in patients with knee or hip OA.
Methods In this observational cohort study, levels of different dimensions of fatigue were 
measured in knee and/or hip OA patients before and after 12 weeks of conservative 
treatment. The cross-sectional and longitudinal relation between (change in) fatigue 
dimensions and (change in) pain or physical function were studied using association 
models, controlling for predefined possible confounders.
Results A total of 231 patients was included, with 47% experiencing severe fatigue. A 
small decrease in levels of fatigue was seen after standardised treatment. The level of 
fatigue severity was cross-sectionally and longitudinally associated with physical function, 
whereas the level of physical fatigue was cross-sectionally and longitudinally associated 
with pain and physical function. No confounders were identified.
Conclusion Important levels of fatigue are common in knee and hip OA patients. After 
evidence-based tailored conservative treatment targeted to improve pain and physical 
function a small decrease of fatigue levels has been found. Reduction of levels of different 
fatigue dimensions were related to change in physical function and pain.
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IntroductIon
In patients with chronic diseases, fatigue is often rated as one of the key factors leading 
to a decreased quality of life.1 Regarding osteoarthritis (OA), a focus group study indicated 
that OA patients experience notable amounts of fatigue that has substantial impact on 
their lives.2 The few studies on fatigue in OA report marked levels of fatigue in nearly half 
of patients.3-6 These findings are comparable with levels found in rheumatoid arthritis (RA).4 
Cross-sectional and some longitudinal data show that a large amount of variability 
exists in (the course of) fatigue in OA patients.4;5 Therefore, identifying variables associated 
with (change in) fatigue could be valuable. Gaining more insight into these factors leads to 
more insight into the pathophysiology of fatigue in OA. Moreover, modifying these factors 
may lead to reduction of fatigue experienced by OA patients. Up to now, several factors 
associated with fatigue in OA have been identified, such as: older age, more pain, less physical 
activity, lower positive affect, depression and lower c-reactive protein (CRP) in serum.4;5;7 Of 
these factors, especially the influence of mental health (depression in particular) and other 
psychosocial factors on fatigue seems to be substantial.5;6 What is more, depression may be 
a factor on the causal pathway between physical function and fatigue.8
Studies concerning fatigue in OA published thus far have some limitations. First, 
included subjects were inadequately characterised, without use of widely accepted 
classification criteria.9;10 Second, no distinction between different dimensions of fatigue – 
like for example, subjective fatigue, concentration, motivation and physical activity - was 
made. It could be hypothesized that increased levels of fatigue solely exist in particular 
dimensions and that each dimension has different determinants. Lastly, aforementioned 
studies were mostly cross-sectional and non-interventional, thus limiting the possibility to 
draw conclusions about direction of causality. 
Fatigue severity in OA seems to be related with clinical and psychological factors; 
however, the precise causal pathway remains unclear. It could be conceived that increased 
fatigue in OA is mainly caused by increased pain and/or decreased physical function. 
This is indeed supported by studies targeting fatigue in RA.11;12 Improvement in pain and 
physical functioning as recommended in treatment guidelines for knee and hip OA13-17 
should – following this line of reasoning – lead to lower levels of fatigue, but this has not 
been studied yet. 
The aims of this study were therefore 1) to investigate levels of different dimensions 
of fatigue in knee and hip OA and 2) to assess changes in fatigue after evidence-based 
tailored conservative treatment targeting to reduce pain and physical functioning and 3) 
to study the cross-sectional and longitudinal relations between (change in) fatigue with 
(change in) pain and physical function in patients with knee and/or hip OA. 
patIents and methods
design
Levels of different dimensions of fatigue were measured in an observational cohort study 
before and after evidence-based tailored multimodal conservative treatment in knee 
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and hip OA patients. Subsequently, the cross-sectional and longitudinal relation (after 
12 weeks of standardised treatment) between the fatigue dimensions and the supposed 
determinants pain and physical function were studied. 
patients
All patients referred to the specialised knee/hip OA outpatient clinic (‘knie/heup artrose 
poli’) at the department of Rheumatology of the Sint Maartenskliniek and participating in 
the COhort of Non-invasively TReated Osteoarthritis of Lower extremities - Pain, function 
and Radiological Outcome (CONTROL-PRO) study were considered for inclusion in this 
study. The main objective of the CONTROL-PRO study is to investigate the disease course 
of patients with moderately advanced (secondary care) knee and hip OA, receiving 
standardised non-invasive multimodal treatment.
For participation in CONTROL-PRO, patients had to fulfil the clinical American College of 
Rheumatology (ACR) criteria for knee and/or hip OA.9;10 For knee OA the following criteria 
were used: knee pain (> 15 days of last month) plus at least three of the following: age > 
50 years, morning stiffness < 30 minutes, crepitus, bony tenderness, bony enlargement, 
no palpable warmth. For hip OA the following criteria were used: hip pain (> 15 days of 
last month) plus internal rotation of the hip < 15° and erythrocyte sedimentation rate 
(ESR) ≤ 45 mm/hr or hip pain (> 15 days of last month) plus internal rotation of the hip ≥ 
15° and painful internal rotation of the hip and morning stiffness ≤ 60 minutes and age 
> 50 years.
Exclusion criteria were: inflammatory rheumatic diseases or deposition diseases 
possibly leading to inflammatory arthritis or secondary OA, co-morbidity exceeding the 
complaints of limitations of knee or hip OA, cognitive or sensomotor problems interfering 
with the use of questionnaires and planned orthopaedic procedures within the next 12 
weeks. Allowed were calcium pyrophosphate deposition disease (CPPD) (excluding the 
phenotypes pseudogout and polyarthritis) and previous meniscus problems.
standardised conservative treatment
Patients who were treated at the knee/hip OA outpatient clinic received standardised 
evidence-based tailored conservative treatment in a stepped-care format as usual care for 
12 weeks if they experienced knee and/or hip pain on a numeric rating scale (NRS, 0 - 10) 
higher than 4. The stepped-care model was based on a Dutch multidisciplinary guideline 
(published online) for diagnosis and treatment of knee and hip OA and has been proposed 
by a consensus panel of leading experts in the field of OA in The Netherlands.18;19
The goal of the intervention was to reduce the level of pain on the NRS to 4 or lower. 
The study visits were planned at week 0 and 12 at the outpatient clinic and at week 4 and 
8 by telephone and managed by a research physician (GS), a physician assistant or a nurse 
practitioner (MA). When NRS pain remained higher than 4 and patients had adequately 
taken the prescribed medication for at least two weeks, treatment options outlined in the 
next step of the stepped-care model were offered.
The first step of the treatment protocol consisted of education, life style advice 
concerning physical activity and weight loss in patients with a body mass index (BMI) of 28 
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or higher (goal 5% weight loss in 12 weeks), referral for physical therapy (prescription for 
both aerobic and strengthening exercises according to the graded activity principle20), and 
treatment with paracetamol (acetaminophen) in a fixed dose of thrice a day 1000 mg (in 
case of no recent use for knee and/or hip complaints). In the second step, if necessary, and 
no earlier than after 4 weeks a Non-Steroidal Anti-Inflammatory Drug (NSAID) was added. 
Our preferential order being naproxen twice a day 500 mg, followed by substitution for 
meloxicam once a day 15 mg, or ibuprofen thrice a day 600 mg at week 8 when necessary 
(step 3). Step 4 includes the substitution of the NSAID for tramadol (thrice a day 50 mg).
To patients with a NRS pain ≤ 4 at baseline all modalities of the protocol were offered, 
but no new analgesics were prescribed.
measurement instruments 
Fatigue
Fatigue was assessed by the Checklist Individual Strength (CIS).21 This 20-item patient 
assessed questionnaire consists of 4 subscales: 1) fatigue severity (CIS-fatigue, 8 items, 
range: 8-56, for example “I feel tired”), 2) reduction in concentration (CIS-concentration, 5 
items, range: 5-35, for example “My thoughts easily wander”), 3) reduction in motivation 
(CIS-motivation, 4 items, range: 4-28, for example “I feel no desire to do anything”) and 
4) reduction in physical activity (CIS-activity, 3 items, range: 3-21, for example “I don’t do 
much during the day”). Each item is scored on a 7-point Likert scale. Furthermore, CIS-
fatigue was divided into three classes: 1) ‘normal’ experience of fatigue (normal fatigue) 
when scores below 27 were measured (mean score for healthy controls plus one standard 
deviation (SD)22), 2) ‘moderate’ experience of fatigue (moderate fatigue) when scores lie 
between 27 and 34 and 3) ‘severe’ experience of fatigue (severe fatigue) when values of 
35 or higher were calculated (scores comparable with fatigue as experienced by patients 
with chronic fatigue syndrome).21 The CIS has proven to be a reliable and valid instrument 
in various conditions.22-24
Pain, patient global assessment, stiffness and physical functioning
To measure pain, stiffness and physical functioning the Likert scale version of the Knee/
Hip injury and Osteoarthritis Outcome Score (KOOS / HOOS) questionnaire was used. 
KOOS / HOOS questionnaires include the Western Ontario McMaster Universities OA 
index (WOMAC) in its complete and original format (with permission, http://www.koos.
nu). WOMAC pain, stiffness and function subscales were calculated (0 to 100, where 0 
equals no symptoms). In addition, patient global assessment (PGA) of OA severity was 
measured using a NRS (0 - 10). 
radiographs
Bilateral (posterior-anterior, fixed flexion and lateral) knee and pelvic radiographs were 
performed in all participants.25 The joint with most complaints at baseline was graded 
according to the Kellgren-Lawrence grading scale (K&L-score).26 All radiographs were read 
by an experienced rheumatologist and/or a trained research physician (GS).
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data collection and management
Demographics, radiographs and data on previously used treatment modalities concerning 
knee and/or hip OA and data on symptoms were obtained in all patients. Questionnaires 
were collected at baseline and after 12 weeks. 
statistics
Statistical analyses were performed using STATA/IC 10.1 for Windows. In patients 
with incomplete baseline or follow-up data, multiple imputation was performed using 
regression modelling to replace missing values. Descriptive statistics were provided. 
Levels of fatigue before and after 12 weeks treatment were compared using a χ2-test (for 
nominal variables), a paired t-test or Wilcoxon signed-rank test (for continuous variables, 
depending on distribution). The subscale CIS-fatigue was divided into three classes as 
mentioned above. Effect sizes (ES) were, when applicable, calculated using the following 
formula: difference between mean before and mean after the intervention divided by the 
SD of the variable. 
Although pain and physical function were relative highly correlated (r = 0.83), the 
variance inflation factor (VIF) indicated no problematic multicollinearity (VIF = 3.2). 
Association models were built with one of the fatigue dimensions as dependent 
variable and both pain (WOMAC pain) and physical function (WOMAC function) as central 
determinants. Regarded as potential confounders were: age, gender, body mass index 
(BMI), index joint (knee or hip), duration of complaints, K&L-score, and past treatment. 
The variables were added to the model one by one to test for possible confounding 
(cut-off for relevant change in the regression coefficient (β) of physical functioning and 
pain was 10% or more). The same procedure was followed to study the association of 
change in fatigue after 12 weeks (dependent variable) with change in pain and physical 
functioning as central determinants. All models were checked for heteroscedasticity and 
non-normality of residuals using visual inspection of residual plots.
ethics
The local Medical Research Ethics Committee (MREC), region Arnhem-Nijmegen (The 
Netherlands) approved the study design of CONTROL-PRO (local study number 2009/095). 
Moreover, all procedures followed were in accordance with the Helsinki Declaration. All 
participants gave their written informed consent.
results
Between April 2008 and February 2010, 292 knee and/or hip OA patients fulfilled inclusion 
criteria of which 231 had sufficient follow-up data (Table 1). Main reason for insufficient 
data was loss of follow-up. No clinical relevant baseline differences were found between 
patients with and without sufficient follow-up data. 
Data regarding CIS subscales are depicted in Table 2. Patients with knee and/or hip 
OA in our study experienced significantly more fatigue in two dimensions (CIS-fatigue and 
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Table 1. Baseline characteristics of patients (n=231) 
Variable
Women, n (%) 150 (65)
Age (years), mean (SD) 54 (10)
BMI, median (p25-75) 28 (25-32)
Knee OA, n (%) 192 (83)
Duration of knee or hip complaints (years), median (p25-75) 4 (2-11)
K&L-score ≥ 2, n (%) 128 (56)
Past treatment, n (%)
   Analgesics 
      Paracetamol in adequate dose1
      One or more NSAID’s
   Physical therapy 
NRS pain (0-10), mean (SD)
NRS PGA (0-10), mean (SD)
WOMAC pain (0-100), mean (SD)
WOMAC stiffness (0-100), mean (SD)
WOMAC function (0-100), mean (SD)
62 (27)
158 (68)
148 (64)
5.9 (2.1)
6.3 (2.2)
53 (22)
57 (24)
54 (23)
Higher scores indicate poorer outcome unless stated otherwise.
1Adequate dose: 2-4 times 1000mg/day during at least 14 consecutive days; 2 Higher score 
indicates better outcome.  BMI body mass index; OA osteoarthritis; K&L-score Kellgren-
Lawrence Grading Scale; paracetamol acetaminophen; NSAID non-steroidal anti-
inflammatory drug; NRS numeric rating scale; PGA patient global assessment; WOMAC 
Western Ontario McMaster Universities score.
Table 2. Levels of fatigue dimensions before and after standardised conservative 
treatment (n=231)
Variable Baseline Week 12 Change 95 % CI ES
CIS-fatigue 31.8 (13.6) 30.2 (13.6) - 1.6 - 0.3 to - 3.0 0.12
CIS-concentration 13.8 (8.1) 13.1 (7.8) - 0.8 -1.6 to 0.07 -
CIS-motivation 11.9 (6.2) 11.3 (5.6) - 0.6 - 1.3 to 0.06 -
CIS-activity 12.1 (5.5) 11.1 (5.6) - 1.0 - 0.4 to - 1.6 0.18
Severe fatigue (%)1 47.2 36.8 - 10.4
Moderate fatigue (%)1 19.1 22.9 4.0
Normal fatigue (%)1 33.8 40.3 6.5
Numbers are mean (SD) unless stated otherwise. 1 CIS-fatigue was divided into 3 classes: 
Normal fatigue (CIS-fatigue < 27), Moderate fatigue (CIS-fatigue between 27 and 35), 
Severe fatigue (CIS-fatigue 35 or higher). CIS Checklist Individual Strength; ES effect size 
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CIS-activity) compared to data on healthy controls from the literature (31.8 versus 17.3 
and 12.1 versus 6.6, respectively).24;27 A total of 28/231 (12%) participants received only 
non-pharmacological treatment during the 12-week treatment period, whereas all other 
individuals had at least one additional pharmacological intervention.
At the group level, there was a small (significant) decrease of CIS-fatigue and CIS-
activity after 12 weeks evidence-based tailored conservative treatment. At baseline, 109 
patients (47%) met the criteria for severe fatigue (i.e. CIS-fatigue ≥ 35) and this decreased 
to 85 patients (37%) after 12 weeks. 
After 12 weeks of evidence-based tailored conservative treatment improvements in 
NRS pain (from 5.9 to 4.9, p < 0.001, ES = 0.48), WOMAC pain (from 53 to 47, p < 0.001, 
ES = 0.27) and physical function (from 54 to 47, p < 0.001, ES = 0.31) were found.
In the cross-sectional model (Table 3), physical function was independently associated 
with CIS-fatigue at baseline. Pain was not independently associated with CIS-fatigue. 
Physical function was also independently associated with CIS-activity at baseline. For the 
cross-sectional model no confounders were identified.
In the longitudinal model (Table 4), change in CIS-fatigue after 12 weeks conservative 
treatment was not associated with baseline physical function and pain levels. However, 
change in CIS-fatigue was independently associated with improvement of physical 
function. No confounders could be identified for this relation. Change in CIS-fatigue 
was not associated with improvement of pain. Change in CIS-activity after 12 weeks 
conservative treatment was not associated with baseline physical function and pain levels. 
However, change in CIS-activity was independently associated with improvement of pain 
and physical function. No confounders could be identified for this relation. 
Table 3. Cross-sectional association model with baseline fatigue scores as dependent 
variables and WOMAC-subscales as central determinants
Variable β 95 % CI
CIS-fatigue
WOMAC function 0.38 0.27 to 0.50
WOMAC pain - 0.08 - 0.20 to 0.04
R2 = 0.29
CIS-activity
WOMAC function
WOMAC pain
R2 = 0.16
0.14
- 0.06
0.08 to 0.19
- 0.11 to 0.01
CIS Checklist Individual Strength; WOMAC Western Ontario McMaster Universities score
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dIscussIon
The results of the current study show that levels of fatigue severity, and to a lesser extent 
physical fatigue, are high in patients with well characterized knee and hip OA, with nearly 
half of the patients experiencing severe fatigue. Evidence-based tailored conservative 
treatment resulted in a small decrease of experienced fatigue. Reduction of fatigue 
severity was found to be related to physical function, whereas reduction of physical 
fatigue seemed to be related to level of physical function and pain. To our knowledge, this 
is the first study to evaluate the impact of recommended medical treatment on different 
dimensions of fatigue in symptomatic OA.
Our study confirms that fatigue, and even severe fatigue, is highly prevalent amongst 
patients with knee and/or hip OA. This is not only true for fatigue severity, but also for 
physical fatigue. Motivational fatigue and concentration, however, are not affected. 
Of note, direct comparison of CIS subscale levels in present study and levels in healthy 
controls is difficult since the latter consisted of 53 healthy individuals (mean age 31.1, 
SD 11.5) matched with patients with chronic fatigue syndrome and multiple sclerosis.24 
However, also by indirect comparison it can be assumed that OA patients experience 
more fatigue (measured with the CIS) than healthy persons as levels of CIS-fatigue in our 
OA cohort are quite similar with levels in RA patients and RA patients are known to have 
increased fatigue levels. 
The findings in our study are in line with the sparse existing data on fatigue in OA2;4;5 
and underscore that fatigue is indeed an important issue in patients with OA. Measured 
levels of fatigue are comparable to levels seen in inflammatory rheumatic diseases like 
RA3-5;11;12;28 and ankylosing spondylitis29 and somewhat higher than observed in psoriatic 
arthritis.30
It should be noted that no control group was used, therefore bias by, for example, 
regression to the mean or placebo effect cannot be ruled out. To our knowledge only 
one other longitudinal study that assessed fatigue after standardised treatment in OA 
Table 4. Longitudinal association model with fatigue change scores as dependent 
variables and changes of WOMAC-subscales as central determinants
Variable β 95 % CI
Change in CIS-fatigue
Change WOMAC function 0.12 0.01 to 0.23
Change WOMAC pain
R2 = 0.02
Change in CIS-activity
Change WOMAC function
Change WOMAC pain
R2 = 0.09
- 0.04
0.06
0.04
- 0.14 to 0.06
0.008 to 0.10
0.0003 to 0.09
CIS Checklist Individual Strength; WOMAC Western Ontario McMaster Universities score
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is published. This randomised controlled trial assessed the effect of a self-management 
program in knee OA patients, and found no significant decrease in fatigue and physical 
function after 12 months, whereas pain decreased significantly.31 This is in line with the 
results from present study indicating that fatigue severity is related to improvement of 
physical function and not to pain. 
Regarding the underlying mechanism of fatigue in OA, our data suggest that fatigue 
severity is partly determined by physical function, whereas physical fatigue is determined 
by both physical function and pain. These associations where found in both our cross-
sectional as well as in our longitudinal analyses. As our standardised treatment included 
interventions explicitly targeting pain and physical function including life style advice, 
physical therapy and analgesics, we may conclude that the direction of causality is that 
decrease of physical function induces more severe fatigue and that decrease in pain, 
in addition to increase in physical function, improves physical fatigue. The finding that 
different dimensions of fatigue in rheumatic diseases have different determinants has 
not been demonstrated yet. A recently published prospective cohort study indicated that 
fatigue is determined by physical function8 which is in concordance with our study. 
In this study no confounders were identified. However, fatigue certainly depends 
on other not-measured variables (e.g. psychosocial factors), as indicated by the low to 
moderate explained variance found. Furthermore, present study was primarily set up to 
investigate the relation between fatigue and physical function and between fatigue and 
pain, because these are the main domains targeted in conservative treatment of OA.
The study cohort that was used - symptomatic knee and hip OA in secondary care - is 
comparable with other cohorts, consisting mainly of obese women with knee OA.32;33 
However, the level of pain and BMI were higher and patients were younger, possibly 
reflecting some selection to a cohort with individuals with relatively high levels of 
complaints. This should, however, not have lead to biased inferences. 
Future research should be directed to answer several important remaining questions. 
Although the decreases of levels of fatigue after evidence-based tailored conservative 
treatment are only modest, it is possible that the maximum effect of the intervention is 
not yet reached after 12 weeks. Another explanation for that only a moderate effect on 
fatigue was found could be that individuals with high levels of experienced fatigue are 
probably unwilling to attend physical therapy or change their life style. Besides, it could be 
presumed that a more intensive multidisciplinary approach to improve function and pain 
will result in a more substantial decrease of fatigue levels. Furthermore, given the relatively 
low ES found, an approach especially targeted to reduce fatigue will have much greater 
effects. To realize this, more insight is required in the underlying mechanisms regarding 
fatigue in OA, with for example depression and sleep disturbances34 being potential causal 
factors. Targeting these domains could potentially reduce fatigue levels in OA.
In summary, high levels of fatigue are very common in knee and hip OA and are 
associated with physical function and pain. Evidence-based tailored conservative treatment 
targeted at improvement of physical function and pain also leads to a small reduction 
of fatigue levels, with change in fatigue severity being related to physical function and 
change in physical fatigue being related to pain and physical function.
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general IntroductIon
Osteoarthritis (OA) is the most common rheumatic disease, with the knee and the hip 
being one of the most affected joints. OA results from an imbalance between synthesis 
and degradation of the extra-cellular matrix of articular cartilage. Because no disease 
modifying agents are available up to now, evidence-based treatment options for daily 
clinical practice are aimed to reduce symptoms and consist of non-surgical and surgical 
modalities. Non-surgical modalities are divided in non-pharmacological (e.g. education, 
exercise, weight reduction) and pharmacological (i.e. analgesics) treatment options. The 
most important surgical treatment option for knee and hip OA is joint replacement. Due 
to the drawbacks of joint replacement surgery and the increasing incidence of OA in the 
ageing population, effective conservative treatment for knee and hip OA is highly needed. 
Therefore, the aim of this thesis was to improve (the use of) conservative treatment for 
knee and hip OA.  
chapter 2
To assess the OA-related health care utilization, baseline and two-year follow-up data 
from the nationwide study, Cohort Hip and Cohort Knee (‘Cohort Heup En Cohort Knie’, 
CHECK), was analysed. CHECK is a 10-year prospective cohort study of 1002 individuals 
with early symptomatic OA of hip and/or knee in The Netherlands. Identifying (modifiable) 
factors that predispose individuals with OA as persistent non-users or high users of health 
care could help health professionals to optimize the patients’ use of health care system. 
Therefore, the aim of the study presented in Chapter 2 was to describe and predict health 
care utilization (HCU) over time in individuals with early hip and knee OA.
Six forms of health care services were distinguished: use of analgesics and/or supplements, 
contact with a general practitioner, an allied health professional, secondary care or alternative 
care. By use of median split, high-overall users of health care were identified. Participants 
without HCU at baseline and two years were labelled as persistent non-users. 
The results show that the majority of patients reported HCU at baseline and at two 
years, with no difference between individuals in the hip (n=588) and knee (n=832) group. 
After two years of follow-up, contact with health care providers decreased in both groups, 
whereas use of analgesics remained stable. Compromised physical health and previous 
use of health care were the strongest predictors for future high overall HCU in both 
groups. Less joint stiffness, better physical health and greater range of motion were the 
strongest predictors for persistent non-use of the health care system. 
chapter 3
Up to now, no disease modifying OA drug (DMOAD) is available in clinical practice. In recent 
years, research on possible DMOADs, including doxycycline, is intensified. Doxycycline has 
been studied before in human OA in one clinical trial, in which doxycycline was found - 
albeit not the primary study objective - to retard progression of radiographic knee OA, 
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with a relatively mild toxicity profile. No effect on pain was found, possibly due to low pain 
scores at enrolment, although flares of pain seemed to occur less frequently. Therefore, 
the clinical important question whether doxycycline can reduce symptoms of OA was 
unanswered. Thus, in Chapter 3, the effects on reducing symptoms of doxycycline in 
knee OA were investigated in a randomised triple-blinded controlled trial. A total of 232 
symptomatic knee OA patients were treated with doxycycline or placebo twice a day for 
24 weeks to study the effects of doxycycline on OA-related symptoms. At the end of 
the study, no difference on proportion of patients with a treatment response was found, 
although a total of 72/232 (31%) met the OMERACT-OARSI responder criteria. Also, no 
difference in secondary endpoints (i.e. pain, stiffness, physical function, patient global 
assessment and quality of life) was found. However, individuals treated with doxycycline 
experienced significantly more adverse events (i.e. sun sensitivity) and more often ceased 
treatment because of side effects compared to the placebo-group. Therefore, the 
conclusion was drawn that doxycycline does not exhibit a symptom-modifying effect in 
knee OA but is associated with an increased chance of toxicity. 
chapter 4
Although interventions recommended in several treatment guidelines have proven 
to be effective in reducing symptoms of knee and hip OA, the combined efficacy was 
never investigated. In Chapter 4, the results of implementation of an evidence-based 
treatment protocol (based on existing treatment guidelines) for symptomatic knee and/
or hip OA are presented. This protocol, based on the multidisciplinary patient-centred 
stepped-care strategy for conservative treatment of hip or knee OA, known as BART 
(‘Behandelstrategie ARTrose’, Beating OA), was implemented at a specialised outpatient 
clinic at the outpatient clinic of the Rheumatology department of the Sint Maartenskliniek. 
The 183 included patients received standardised evidence-based tailored conservative 
treatment in a stepped-care format for 12 weeks. The goal of the intervention was to 
reduce the level of pain on a numeric rating scale (NRS, 0-10) to 4 or lower. The protocol 
consisted of treatment with analgesics, education, life style advices concerning physical 
activity, weight loss advices in obese patients and referral for physical therapy. When NRS 
pain remained higher than 4, a new analgesic was offered. After 12 weeks conservative 
treatment according to the protocol, 86/183 (47%) patients had reached a treatment 
response according to the OMERACT-OARSI responder criteria, whereas 71/183 (39%) 
reached a NRS pain ≤ 4. Moreover, improvements of pain, physical function and patient 
global assessment were found.
A remarkable finding was that the vast majority of patients has not been exposed 
adequately to conservative treatment modalities for knee and/or hip OA in the past 
(81%). Particularly physical therapy and paracetamol were under-used. This is striking, 
especially when keeping in mind that the majority of patients were already considered for 
joint replacement in secondary care. 
The only identified independent predictor for an OMERACT-OARSI response after 
12 weeks conservative treatment was the number of previously used non-steroidal 
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anti-inflammatory drugs (NSAIDs). Therefore, treatment response could largely not be 
predicted. Possibly other non-measured variables play a role as well. 
Consequently, all individuals with symptomatic knee and/or hip OA referred to 
secondary care have the same chance to respond to conservative treatment and this 
should be offered before considering joint replacement. 
chapter 5
Studies on pharmacological pain management strategies in OA are lacking. Therefore, 
an in-dept study of analgesic treatment using an evidence-based treatment protocol was 
undertaken and described in Chapter 5. The protocol consisted of education, life style 
advices concerning physical activity and weight loss advices in addition to NRS-guided 
prescription of analgesics. The first step of pharmacological pain management was 
treatment with paracetamol in a fixed dose of thrice a day 1000 mg in case of no recent 
use in adequate dosage. In the second step, if necessary and not earlier than after 4 
weeks, a NSAID (NSAID 1) was advised. The next step consisted of substitution of NSAID 1 
for NSAID 2. The main outcomes were the proportions of patients reaching a NRS pain ≤ 
4 after each step. In addition, predictors for a response (i.e. NRS pain ≤ 4) to paracetamol 
and NSAID 1 were identified. 
A total of 347 patients was included. Of these patients, 234 were treated with 
paracetamol, 190 with NSAID 1 and 87 with NSAID 2, with response percentages of 25, 
17 and 11%, respectively. A few independent predictors for response to analgesics were 
identified: i.e. higher age, lower patient global assessment, lower stiffness and higher 
Kellgren & Lawrence grading scale (K&L-score) for response to paracetamol and lower 
patient global assessment for response to NSAID 1. 
A total of 138 out of 302 (46%) patients did not start with a (new) NSAID after failing 
paracetamol or the first NSAID (i.e. persistent NRS pain > 4). Reasons for failure to follow 
the advice of the treating physician were mainly unwillingness by the patients to take a 
(new) NSAID (39%) or acceptable pain level (12%). In 28% no reason could be identified, 
possibly reflecting inadequate offering of the next step of the protocol by the treating 
physician. Other reasons for not switching to a (new) NSAID were: contra-indication (7%) 
and start of different pharmacological treatment (14%). 
In conclusion, prescription of paracetamol and prescription of a NSAID after insufficient 
results with paracetamol seems appropriate in patients with severe knee and/or hip OA, 
even after prior consideration for joint replacement. The results of switching to a second 
NSAID after failing paracetamol and a NSAID are disappointing. 
chapter 6
In Chapter 6 of this thesis, a study on fatigue in knee and/or hip OA is presented. Clinical 
practice and a few studies performed on fatigue and OA suggest that fatigue is a common 
complaint of patients suffering from OA. The study in Chapter 6 aimed to answer the 
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question whether fatigue in knee and/or hip OA patients is reduced by standardised 
conservative treatment as recommended by the treatment guidelines for knee and hip OA. 
Moreover, the relationships between fatigue and pain and fatigue and physical function 
were investigated. 
A total of 231 patients with knee and/or hip OA were included in this study. The study 
patients experienced increased fatigue in two of the four domains of fatigue: fatigue 
severity and fatigue during activity. A total of 47% of patients experienced severe fatigue 
at baseline (i.e. fatigue levels comparable with patients with chronic fatigue syndrome). 
After 12 weeks standardised conservative treatment, a small but significant decrease of 
fatigue severity and fatigue during activity was measured. In the cross-sectional model 
physical function was independently associated with fatigue severity, whereas pain 
was independently related to fatigue during activity. Change in fatigue severity was 
independently related to improvement of physical function, whereas change in fatigue 
during activity was independently related to reduction of pain and improvement of 
physical function.
Regarding the underlying mechanism of fatigue in OA, the presented data suggest 
that fatigue severity is partly determined by physical function, whereas fatigue during 
activity is determined by both physical function and pain. These associations where found 
in both the cross-sectional as well as in the longitudinal analyses. 
In conclusion, fatigue is common in secondary care knee and hip OA. Conservative 
treatment as recommended by evidence-based guidelines results in a modest improvement 
of fatigue levels. Finally, change in fatigue is related to change in pain and physical function.
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maIn conclusIons of thIs thesIs
The main conclusions of this thesis are:
 » The majority of individuals with early knee and/or hip OA report persisting health care 
utilization for OA during two years. (Chapter 2)
 » Future use of OA-related health care in early knee and/or hip OA is highly variable but 
predictable to a certain extent. (Chapter 2)
 » Doxycycline has no symptom-modifying effect in patients with symptomatic knee OA, 
but is associated with an increased risk of adverse events. (Chapter 3)
 » The majority of patients with knee and  hip OA referred to secondary care (81%) was 
insufficiently conservatively treated in primary care in The Netherlands. (Chapter 4)
 » Evidence-based tailored conservative treatment using a standardised protocol is suc-
cessful in 47% of secondary care knee and/or hip OA patients. (Chapter 4)
 » Response to evidence-based tailored conservative treatment using a standardised pro-
tocol is largely not predictable. Therefore, these treatments should be offered to all 
patients. (Chapter 4)
 » Protocolised prescription of paracetamol and the first NSAID after failing paracetamol 
results in moderate treatment response percentages, but the result of the second 
NSAID is disappointing in patients with advanced knee and/or hip OA. (Chapter 5)
 » The treatment response to analgesics in knee and/or hip OA is predictable to a certain 
extent. (Chapter 5)
 » High levels of fatigue are very common in patients suffering from knee and/or hip OA 
in secondary care. (Chapter 6)
 » Evidence-based tailored conservative treatment leads to a small reduction of fatigue 
levels, with change in fatigue severity being related to physical function and change in 
fatigue during activity being related to pain and physical function. (Chapter 6)
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The aim of this thesis was to improve the conservative treatment of knee and hip 
osteoarthritis (OA). In this chapter the main findings of the studies presented in this thesis, 
their clinical implications and future research will be discussed. 
maIn fIndIngs, clInIcal ImplIcatIons and future research
health care utilization
The results of our study on health care utilization (HCU) in early knee and hip OA indicate 
that a variety of health care resources are used over a two-year period and that HCU 
is variable between subjects. Although HCU in OA is known to be highly variable,1-12 
predictors for future HCU were not described before. The strongest predictor we 
were able to identify was previous HCU, rather than disease related variables as pain 
and limitations in activity. Moreover, around 10% of the early OA patients had already 
attended a caregiver in secondary care, despite the fact that the majority of patients did 
not attend an allied health care provider or used pharmacological treatment. The results 
suggest that education of patients and caregivers on appropriate treatment options for 
OA might result in more appropriate stepped-care future HCU. 
evidence-based conservative treatment
As indicated by the studies presented in Chapter 4 and 5, multimodal treatment 
according to the existing guidelines13-16 improves the symptoms of patients with knee 
and hip OA. Even in secondary care knee and hip OA patients, already considered for 
joint replacement, nearly 50% of patients reached an OMERACT-OARSI response17 using 
a short term, simple standardised and feasible treatment protocol. Because a treatment 
response is not predictable, every patient with symptomatic knee and/or hip OA referred to 
secondary care should first be treated conservatively before considering joint replacement. 
However, to tailor treatment future research should focus on identifying predictors for 
response to treatment. Then, treatment can be tailored to individuals with the best chance 
to respond. With this approach, unnecessary prescription of potential toxic agents18;19 
could be prevented. Another approach to reduce adverse events is the development 
of cyclooxygenase-inhibiting nitric oxide donators (CINODSs). This new class of drugs 
combines a parent non-steroidal anti-inflammatory drug (NSAID) with nitric oxide, with the 
aim of reducing potential toxicity of the parent drug while maintaining the analgesic and 
anti-inflammatory effects. Results of a few studies on CINODs in OA are promising as they 
indeed indicate less adverse events compared to NSAIDs, while maintaining efficacy.20;21
To improve the results of conservative treatment, research should be focussed on 
improvement of the treatment strategy. As pharmacological pain management strategies 
have not been published before, we cannot compare our results. Perhaps, implementation 
of weak opioids22 or intra-articular steroid injections23 should be applied in the pain 
management strategy in OA. Moreover, a trial period of 4 weeks for an analgesic 
might be too long and could therefore be shortened.24 Another point to consider is the 
appropriateness of a cut-off point NRS pain ≤ 4 for each individual patient, because we 
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found that a substantial part of the patients was satisfied even with a NRS pain > 4. It 
may be worthwhile to explore the feasibility of individualized cut-off points. Additionally, 
barriers for use of analgesics - e.g. cognitive or emotional factors could play a role - should 
be investigated. 
The results of conservative treatment in knee and hip OA might be improved further 
by the development and implementation of effective interventions to motivate patients to 
adhere to treatment and to apply the advised life style changes, as the results of the study 
described in Chapter 4 indicate that only a minority of the obese patients actually looses 
weight despite the advices from the caregiver. 
We found in our studies that the vast majority of patients had not been adequately 
treated with conservative modalities in primary care before referral to secondary care 
for joint replacement. These findings are in concordance with some earlier studies on 
adherence to treatment guidelines for knee OA.25;26 Thus, efforts should be made to 
improve adherence to evidence-based treatment guidelines for OA. A first step is already 
made since the multidisciplinary patient-centred stepped-care strategy for conservative 
treatment of hip or knee OA (i.e. BART) was proposed by a leading expert panel in The 
Netherlands.27 At this moment this strategy is implemented in primary care in a research 
setting. Hopefully, this approach will lead to more timely and appropriate referrals to 
secondary care and to a reduction of undesirable use of secondary care treatment options, 
because even in early knee and/or hip OA high secondary care consumption is reported 
while simple first line treatment options were underutilized.  
fatigue
The study in Chapter 6 shows that fatigue is a common complaint in patients suffering 
from knee and hip OA. This is in concordance with the few prior studies on fatigue 
in OA28-30 and comparable to inflammatory diseases like rheumatoid arthritis.31 Our 
study - although uncontrolled - indicated that standardized evidence-based conservative 
treatment results in a modest reduction of fatigue levels. Only one other treatment study 
on fatigue in OA has been published, which shows no effects of a self-management 
program on fatigue levels.32 
Our data and data from another study33 suggest that fatigue severity is partly 
determined by physical function and not by pain. In contrary, physical fatigue is determined 
by both physical function and pain. This indicates that fatigue severity and pain as well 
as the different dimensions of fatigue have different underlying mechanisms. Moreover, 
fatigue is determined by other variables, like depressive symptoms and coping strategies. 
However, a recent paper suggests that depressive mood is an intermediate variable in 
the relation between pain/physical function and fatigue.33 Future studies are necessary to 
explore the link between OA and fatigue, to be able to further modify OA-related fatigue. 
new treatment options 
As reported in Chapter 6, doxycycline failed to show symptom-modifying effects in knee 
OA, although the only earlier study in human OA demonstrated structure-modifying 
effects and suggested some symptom-improving effects.34 Besides being able to reduce 
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structural disease progression, a disease-modifying OA drug (DMOAD) should preferably 
exhibit symptom-modifying properties, since structural (radiographic) abnormalities 
only modestly correlate with OA-related symptoms.35;36 Therefore, efforts should be 
made to unravel the mechanisms underlying symptoms in OA. Probably, other structural 
abnormalities than radiographic signs are more correlated with patient’s complaints. A 
novel possibility to reduce OA-related pain is inhibiting nerve growth factor, which is 
increasingly expressed in inflamed tissue. Although the results on pain reduction in the 
first studies with antibodies to nerve growth factor were impressive, some reports of 
severe adverse events urge to caution.37-39 
Finally, modern imaging techniques like ultrasonography40 and magnetic resonance 
imaging (MRI)41 could possibly link structural abnormalities with the symptoms of the 
individual patient and probably bring in novel treatment targets and the opportunity to 
tailor the management for individuals with OA. 
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IntroductIe
Artrose (in de Engelstalige literatuur: Osteoarthritis (OA)) is de meest voorkomende 
reumatische aandoening en manifesteert zich vaak in de knie of heup. Geschat wordt 
dat artrose van de knie en heup bij respectievelijk 74 per 1000 en 56 per 1000 individuen 
voorkomt in de leeftijdscategorie van 60-64 jaar in Nederland. Artrose wordt gekenmerkt 
door een disbalans tussen de aanmaak en afbraak van gewrichtskraakbeen. Echter, 
ook andere structuren in het gewricht blijken betrokken te zijn bij artrose, zoals het 
gewrichtsslijmvlies (synovium), het onderliggende (subchondrale) bot, pezen, spieren en 
slijmbeurzen. Daarom wordt artrose tegenwoordig als een aandoening van het gehele 
gewricht gezien. 
Het precieze ontstaansmechanisme van artrose is onbekend. Belangrijke risicofactoren 
voor het ontstaan van artrose zijn: leeftijd, vrouwelijk geslacht, familiair voorkomen, 
aangeboren afwijkingen, overgewicht, gewrichtsschade en overmatige belasting van 
het gewricht in het verleden. Risicofactoren voor progressie van artrose zijn onder 
andere: standsafwijkingen, spierzwakte en overgewicht. De klachten van artrose 
bestaan met name uit pijn, stijfheid en beperkte beweeglijkheid van de gewrichten en 
variëren sterk van persoon tot persoon, maar ook binnen een persoon. Röntgenfoto’s 
kunnen gewrichtsspleetversmalling, botuitgroeiingen (osteofyten), verdichting van het 
onderliggende bot (subchondrale sclerose) en cysten tonen. Echter, de radiologische 
afwijkingen komen vaak niet overeen met de klachten van de patiënt, zodat de diagnose 
vaak zonder het maken van een röntgenfoto wordt gesteld. Bloedonderzoek is in de regel 
niet afwijkend bij artrose. 
Omdat er tot op heden nog geen behandelingen beschikbaar zijn die het artroseproces 
kunnen beïnvloeden, richt de behandeling van artrose zich op het verminderen van 
de symptomen van artrose. De aanbevelingen die gedaan worden in de beschikbare 
evidence-based richtlijnen bestaan uit conservatieve (niet-chirurgische) en chirurgische 
behandelopties. De conservatieve behandelopties bestaan uit niet-farmacologische en 
farmacologische behandelingen. Niet-farmacologische behandelingen voor knie- en 
heupartrose bestaan uit educatie, leefstijladviezen, fysiotherapie (spierversterking en 
conditieverbetering) en indien er sprake is van overgewicht, het advies om af te vallen. De 
farmacologische behandelopties bestaan met name uit het voorschrijven van paracetamol 
en ontstekingsremmende pijnstillers (NSAIDs), en eventueel zwakwerkende opioïden en 
injecties met corticosteroïden. De chirurgische behandeling van knie- en heupartrose 
bestaat vooral uit gewrichtsvervangende operaties. In het algemeen wordt geadviseerd een 
gewrichtsvervangende operatie pas uit te voeren indien er onvoldoende resultaat is van de 
conservatieve behandeling. Een nadeel van een gewrichtsvervanging is dat de prothese 
vaak na 10-15 jaar vervangen moet worden, waardoor deze ingreep niet aantrekkelijk is 
voor relatief jonge patiënten met knie- of heupartrose. Tevens blijkt ongeveer één op de 
zes patiënten die een gewrichtsvervanging heeft ondergaan niet tevreden te zijn met het 
uiteindelijke resultaat en bovendien is er een kans op perioperatieve complicaties.
Gezien de toename van het aantal mensen met artrose en bovengenoemde nadelen 
van een gewrichtsvervangende operatie wordt de vraag om effectieve conservatieve 
behandeling van knie- en heupartrose steeds groter. Uit eerder verricht onderzoek blijkt 
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tevens dat conservatieve behandelopties van knie- en heupartrose vaak onvoldoende 
benut worden. Het doel van dit proefschrift was daarom het verbeteren van de 
conservatieve behandeling van knie en heupartrose. Dit bestond onder andere uit de 
volgende onderdelen:
 » het beschrijven van artrose-gerelateerd zorggebruik en het voorspellen van toekomstig 
zorggebruik van patiënten met beginnende knie en/of heupartrose
 » het onderzoeken van het effect van doxycycline op de symptomen van knieartrose
 » het onderzoeken van het resultaat van het toepassen van een op de richtlijnen geba-
seerd behandelprotocol voor knie- en/of heupartrose
 » het onderzoeken van het voorkomen van vermoeidheid bij patiënten met knie- en/
of heupartrose en het effect van het toepassen van het behandelprotocol op de mate 
van vermoeidheid
hoofdstuk 2
In Hoofdstuk 2 wordt een studie beschreven naar het artrose-gerelateerd zorggebruik 
van patiënten uit het Cohort Heup En Cohort Knie (CHECK), een landelijke studie waarin 
1002 individuen met vroege heup- en knieartrose gedurende 10 jaar worden gevolgd. 
Voor het onderzoek in Hoofdstuk 2 werden de baseline en twee-jaars data gebruikt. 
Er werden zes vormen van artrose-gerelateerd zorggebruik onderscheiden: gebruik van 
pijnstillers en voedingsupplementen, contact met de huisarts, een paramedicus of een 
hulpverlener in de tweede lijn en alternatieve zorg. Middels de median-split methode 
werden veel-gebruikers geïdentificeerd. Patiënten die zowel op baseline als na twee jaar 
geen zorggebruik rapporteerden werden aangemerkt als persisterende geen-gebruikers. 
De resultaten tonen dat de meerderheid van de patiënten artrose-gerelateerd zorggebruik 
rapporteerde en dat er geen verschil was tussen de patiënten met beginnende knieartrose 
en patiënten met beginnende heupartrose. Na twee jaar was het aantal contacten met 
hulpverleners afgenomen terwijl het gebruik van pijnstillers gelijk bleef. Verminderde fysieke 
gezondheid en eerder gebruik van zorg bleken de sterkste voorspellers veel zorggebruik in 
de toekomst. Minder stijfheid, betere fysieke gezondheid en grotere bewegingsuitslagen 
van de gewrichten waren voorspellers voor geen-zorggebruik na twee jaar. 
hoofdstuk 3
Hoofdstuk 3 van dit proefschrift beschrijft een placebogecontroleerde gerandomiseerde 
geblindeerde studie naar het effect van doxycycline op de symptomen bij patiënten 
met knieartrose. Tot op heden zijn er geen geneesmiddelen waarvan het onomstotelijk 
is vastgesteld dat zij het artrose-proces kunnen beïnvloeden (de zogenaamde Disease 
Modifying Osteoarthritis Drugs (DMOADs)). Er zijn echter wel een aantal middelen waarvan 
gedacht wordt dat zij deze eigenschap bezitten. Doxycycline, een bekend antibioticum, is 
een van deze geneesmiddelen. Doxycycline blijkt in een eerdere studie de progressie van 
radiologische afwijkingen van knieartrose te remmen. Onbekend was echter of dit middel 
daarnaast ook in staat is om de klachten van artrose te verminderen. 
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In het onderzoek onder 232 patiënten met knieartrose, beschreven in Hoofdstuk 3, 
werd geen verschil gevonden tussen patiënten behandeld met doxycycline en patiënten 
behandeld met placebo voor wat betreft afname van klachten na 24 weken. In totaal 
bereikten 72 van de 232 deelnemers een behandelrespons (OMERACT-OARSI respons) 
na 24 weken behandeling. Echter, het aantal responders was niet verschillend tussen 
beide behandelgroepen. Ook werd er geen verschil gevonden in verbetering van pijn, 
stijfheid, fysiek functioneren en globale inschatting van de ziektetoestand door patiënten. 
Wel bleken er meer patiënten in de doxycycline-groep last te hebben van bijwerkingen 
(met name zonlichtovergevoeligheid) en staakten meer mensen in de doxycycline-groep 
het onderzoek voortijdig wegens bijwerkingen vergeleken met individuen in de placebo-
groep. Geconcludeerd kan worden dat doxycycline geen effect heeft op het verbeteren van 
klachten gerelateerd aan knieartrose, maar wel een verhoogde kans op bijwerkingen geeft.
hoofdstuk 4
Hoewel de behandelingen die geadviseerd worden in de richtlijnen voor de conservatieve 
behandeling van knie- en heupartrose allen bewezen effectief blijken te zijn in klinische 
studies, was het resultaat van het gecombineerd toepassen van deze adviezen niet bekend. 
Daarom werd in de studie die wordt beschreven in Hoofdstuk 4 van dit proefschrift, 
het resultaat van een op evidence-based richtlijnen gebaseerd behandelprotocol 
onderzocht bij 183 patiënten met knie- en/of heupartrose. Het protocol bestond uit 
educatie, leefstijladviezen, verwijzing naar de fysiotherapeut voor spierversterking en 
conditieverbetering, het advies om af te vallen indien er sprake was van overgewicht 
en het stapsgewijs voorschrijven van pijnstillers. Het voorschrijven van pijnstillers werd 
gebaseerd op de mate van pijn gemeten middels een numeric rating scale pijnscore (0-10, 
waar 10 maximaal ervaren pijn betekent). Indien de pijnscore > 4 was werd de volgende 
stap in het voorschrijven van pijnstillers genomen. Als eerste stap gold het voorschrijven 
van paracetamol, gevolgd door een NSAID, eventueel gevolgd door het wisselen van 
de NSAID. Indien nodig (pijnscore > 4) werd als vierde stap tramadol voorgeschreven. 
Patiënten kwamen op baseline en na 12 weken op de polikliniek en werden na 4 en na 8 
weken gebeld om zo nodig de pijnmedicatie aan te passen. Na 12 weken conservatieve 
behandeling bleken 86 van de 183 (47%) patiënten te voldoen aan de OMERACT-
OARSI responder criteria en hadden 71 van de 183 (39%) patiënten een pijnscore ≤ 4. 
Tevens werden er duidelijke verbeteringen gezien in pijn, fysiek functioneren en globale 
inschatting van de ziektetoestand door patiënten. 
Een behandelrespons na 12 weken bleek moeilijk te voorspellen met baseline 
variabelen: de enige geïdentificeerde voorspeller bleek het aantal gebruikte NSAIDs 
voorafgaand aan het onderzoek te zijn. 
Een opvallende bevinding was dat de meerderheid van de patiënten (81%) voorafgaand 
aan het onderzoek geen adequate conservatieve behandeling had gehad in de eerste lijn, 
terwijl er in de meerderheid van de gevallen al wel een gewrichtsvervangende operatie 
overwogen was.
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De conclusie die getrokken kan worden is dat het gestandaardiseerd toepassen van 
de conservatieve behandelingen geadviseerd in de behandelrichtlijnen bij ongeveer 
de helft van de knie- en heupartrose patiënten in de tweede lijn leidt tot een goede 
behandelrespons en dat een goede behandelrespons moeilijk te voorspellen is. Dit 
betekent dat iedere patiënt evenveel kans heeft op een goede behandelrespons en dat 
adequate conservatieve behandeling aan iedere patiënt met knie- en/of heupartrose zou 
moeten worden aangeboden alvorens een prothese wordt overwogen.
hoofstuk 5
Omdat er weinig studies gedaan zijn naar farmacologische behandelstrategieën in de 
conservatieve behandeling van artrose werd een studie verricht (Hoofdstuk 5) naar de 
resultaten van het voorschrijven van analgetica in de verschillende behandelstappen in 
het behandelprotocol beschreven in Hoofdstuk 4. De eerste stap was het starten van 
paracetamol in een dosering van 3 maal daags 1000 mg indien er geen sprake was 
van recent adequaat gebruik van dit middel. De volgende stap was het starten van een 
NSAID (NSAID 1) indien de pijnscore > 4 bleef. De derde stap bestond uit het wisselen 
van NSAID (NSAID 2). In totaal werden er 347 patiënten met knie en/of heupartrose 
geïncludeerd in de studie, waarvan er 210 met paracetamol, 190 met NSAID 1 en 87 met 
NSAID 2 behandeld werden, met responspercentages (pijnscore ≤ 4) van respectievelijk 
25, 16 en 11. Onafhankelijke voorspellers voor respons op paracetamol waren: hogere 
leeftijd, mildere globale inschatting van de ziektetoestand door patiënt, minder stijfheid 
en ernstigere radiologische afwijkingen. Voor respons op NSAID 1 werd de volgende 
voorspeller geïdentificeerd: mildere globale inschatting van de ziektetoestand door 
patiënten.
Bij 138 van de 302 (46%) patiënten werd niet van pijnstiller gewisseld, hoewel dit wel 
werd geadviseerd (pijnscore > 4). In meer dan de helft van deze gevallen was dit de wens 
van de patiënt. In een minderheid van de gevallen werd er geen reden gevonden voor 
het niet-switchen van de medicatie en was er dus mogelijk sprake van het niet adequaat 
aanbieden van de volgende stap van het protocol door de behandelaar. 
Concluderend kan gesteld worden dat het voorschrijven van paracetamol en een NSAID 
na falen van paracetamol leidt tot redelijke responspercentages, terwijl het resultaat van 
het voorschrijven van een tweede NSAID teleurstellend is.
hoofdstuk 6
Uit de klinische praktijk en uit de weinige wetenschappelijke onderzoeken op dit gebied 
blijkt dat vermoeidheid een veel voorkomende klacht is van patiënten met artrose. In 
Hoofdstuk 6 wordt een studie beschreven waarin het voorkomen van vermoeidheid en 
het resultaat van op de evidence-based richtlijnen gebaseerde conservatieve behandeling 
op de vermoeidheid bij knie- en/of heupartrose patiënten werden onderzocht. Daarnaast 
werd de relatie tussen vermoeidheid en pijn en tussen vermoeidheid en fysiek functioneren 
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bestudeerd. Er werden 231 patiënten met knie- en/of heupartrose geïncludeerd in deze 
studie. De patiënten ervaarden vermoeidheid in verhoogde mate in twee domeinen: 
vermoeidheid ernst en fysieke vermoeidheid. Bij 47% van de patiënten was er sprake van 
ernstige vermoeidheid, dat wil zeggen mate van vermoeidheid vergelijkbaar met patiënten 
met het chronisch vermoeidheidssyndroom. Na 12 weken conservatieve behandeling 
werd er een kleine maar significante verbetering gemeten van de vermoeidheid ernst en 
fysieke vermoeidheid. Fysiek functioneren was cross-sectioneel geassocieerd met ernst van 
vermoeidheid, terwijl pijn cross-sectioneel geassocieerd was met fysieke vermoeidheid. 
Verandering van ernst van vermoeidheid was onafhankelijk geassocieerd met verandering 
van fysiek functioneren, terwijl verandering van fysieke vermoeidheid was geassocieerd 
met verandering van pijn en verandering van fysiek functioneren. 
Geconcludeerd kan worden dat conservatieve behandeling zoals aanbevolen wordt in 
de richtlijnen resulteert in een kleine verbetering van vermoeidheid bij patiënten met knie- 
en/of heupartrose. Daarnaast lijkt vermoeidheid ernst gerelateerd aan fysiek functioneren 
en fysieke vermoeidheid aan pijn en fysiek functioneren. 
conclusIes
 » De meerderheid van de patiënten met vroege knie- en/of heupartrose rapporteert per-
sisterend gebruik van artrose-gerelateerde zorg gedurende twee jaar. (Hoofdstuk 2)
 » Toekomstig geen-gebruik en veel-gebruik van artrose-gerelateerde zorg zijn tot op 
zekere hoogte te voorspellen. (Hoofdstuk 2)
 » Doxycycline heeft geen effect op de symptomen van knieartrose, maar geeft wel bij-
werkingen. (Hoofdstuk 3)
 » De meerderheid (81%) van de knie- en/of heupartrose patiënten in de tweede lijn, 
veelal zonder een indicatie voor chirurgisch ingrijpen, heeft onvoldoende conserva-
tieve behandeling gekregen in de eerste lijn.
 » Evidence-based conservatieve behandeling van knie- en/of heupartrose volgens 
een gestandaardiseerd protocol was succesvol bij 47% van knie- en/of heupartrose 
patiënten in de tweede lijn. (Hoofdstuk 4) 
 » Het geprotocolleerd voorschrijven van paracetamol en een NSAID na falen van para-
cetamol is succesvol in 25% van de gevallen, terwijl het wisselen van een NSAID teleur-
stellend is bij patiënten met knie- en/of heupartrose in de tweede lijn. (Hoofdstuk 5)
 » De respons op analgetica bij patiënten met knie- en/of heupartrose in de tweede lijn is 
enigszins te voorspellen. (Hoofdstuk 5)
 » Ernstige vermoeidheid komt veel voor bij patiënten met knie- en/of heupartrose in de 
tweede lijn.
 » Geprotocolleerde evidence-based conservatieve behandeling van knie- en/of heupar-
trose in de tweede lijn leidt tot een kleine verbetering van vermoeidheid. Verandering 
van vermoeidheid ernst is gerelateerd aan verandering van fysiek functioneren, terwijl 
verandering van fysieke vermoeidheid gerelateerd is aan verandering van pijn en fysiek 
functioneren. (Hoofdstuk 6)
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Gijsbreght Frederik Snijders werd op 9 februari 1981 
geboren te Nijmegen en groeide op in Almelo. Hij 
doorliep de gehele Vrije School en behaalde in 2000 
zijn VWO diploma aan het Baudartius College in 
Zutphen. Gijs begon in 2000 de studie Geneeskunde 
aan de Radboud Universiteit in Nijmegen, alwaar hij in 
2007 zijn artsexamen behaalde.
De liefde voor de Reumatologie ontstond tijdens zijn 
introductie-co-schap eind 2004 op het Reumacentrum 
van de Sint Maartenskliniek te Nijmegen onder leiding 
van Dr. M.J.A.M. Franssen. Dit kreeg een vervolg met 
een keuze-co-schap in juni 2006, opnieuw onder 
leiding van Dr. M.J.A.M. Franssen. 
Gijs deed zijn eerste onderzoekservaring op tijdens 
de wetenschappelijke stage in het kader van de studie Geneeskunde in het najaar van 
2006, getiteld: ‘Afbouwen van hoge doses TNF-α-blokkers in reumatoïde artritis’, onder 
leiding van dr. A.A. den Broeder. Deze samenwerking resulteerde in de start van een 
promotieonderzoek in maart 2007 met als onderwerp ‘Conservatieve behandeling van 
knie- en heupartrose’ op het Reumacentrum van de Sint Maartenskliniek onder leiding 
van dr. A.A. den Broeder, dr. C.H.M. van den Ende en prof. dr. P.L.C.M. van Riel (UMC St 
Radboud). De resultaten van dit onderzoek staan beschreven in dit proefschrift.
In zijn jeugd voetbalde Gijs bij s.v. PH Almelo. Sinds het seizoen 2001-2002 komt hij 
uit voor de Nijmeegse zaterdag-derdeklasser Uni v.v. 
Vanaf april 2011 is Gijs begonnen met de vooropleiding Interne Geneeskunde in het 
Canisius Wilhelmina Ziekenhuis te Nijmegen (opleider dr. A.S.M. Dofferhoff) in het kader 
van de opleiding tot reumatoloog (opleider prof. dr. P.L.C.M. van Riel).
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Het voltooien van mijn promotietraject was me nooit gelukt zonder de hulp van velen die 
ik hierbij allemaal hartelijk dank. Daarnaast was het onderzoek niet mogelijk zonder de 
vele knie- en heupartrose patiënten die bereid waren deel te nemen aan de onderzoeken 
beschreven in dit proefschrift. Een aantal belangrijke personen wil ik apart bedanken.
Mijn dank gaat ten eerste natuurlijk uit naar dr. A.A. den Broeder, Alfons, mijn co-
promotor. Herman Lelieveldt beschrijft in zijn boek ‘Promoveren’ (Aksant, 2e herziene 
druk, 2007) twaalf kleine stereotyperingen van begeleiders van promovendi. Ik denk dat jij 
het meest in de buurt komt van ‘de professional’. Deze wordt als volgt omschreven: ‘heeft 
altijd tijd voor je, leest stukken snel, voorziet ze van adequaat commentaar, motiveert 
je, en combineert de rollen van coach en beoordelaar op bewonderenswaardige wijze.’ 
Daarnaast heb je natuurlijk ook trekjes van ‘de hyperactieve’ en ‘de structuralist’. Alfons, 
ik ben heel blij dat jij mij hebt begeleid tijdens mijn promotietraject. Ik heb verschrikkelijk 
veel van je geleerd. Door jou ben ik ‘gevallen’ voor het wetenschappelijk onderzoek en wil 
ik in het vervolg van mijn carrière bij onderzoek betrokken blijven. Dank voor al je privé-
colleges ‘onderzoek’ en voor je positiviteit waarmee je me af en toe uit de put trok als het 
even tegen zat. Ik had me geen betere co-promotor kunnen wensen!
Dr. C.H.M. van den Ende, mijn tweede co-promotor, beste Els of moet ik je ‘Sint’ 
noemen? Je schreef me een heel mooi sinterklaasgedicht eind 2009 toen ik een goede 
afloop van mijn promotietraject even niet meer zag zitten. We zijn daarna meerdere dagen 
samen STATA gaan leren, iets waarvan ik de rest van mijn promotie heel veel baat heb 
gehad (en nu nog steeds). Heel veel dank voor je kritische blik op mijn werk. Als ik jouw 
commentaar op mijn manuscripten had verwerkt wist ik altijd dat het een goed artikel 
was. In veel opzichten zijn jij en Alfons tegenovergesteld aan elkaar. Ik denk dat dat de 
reden is dat jullie een super team zijn!
Prof. dr. P.L.C.M. van Riel, mijn promotor, beste Piet, al was je vooral op de achtergrond 
betrokken bij mijn onderzoek, toch waren onze gesprekken altijd waardevol. Je behield 
altijd het overzicht. Bedankt hiervoor.
Dr. F.H.J. van den Hoogen, directeur Reumacentrum, beste Frank, dank voor je 
vertrouwen dat je me gegeven hebt. Ik herinner me nog goed dat Alfons na het gesprek 
over mijn aanstelling bij me kwam en zei dat jij gezegd had: “Voor één jaar? Nee, neem 
hem maar meteen voor drie jaar aan.” En dat terwijl je mij nog nauwelijks kende! Verder 
heb je er op de een of andere manier gevoel voor om altijd op het juiste moment even bij 
me binnen te lopen en even te vragen hoe het ging. Dit heb ik altijd zeer gewaardeerd. 
Ook wist je altijd precies hoe het met het onderzoek stond, terwijl je er niet direct bij 
betrokken was. Heel veel dank!
Bart van den Bemt, dank voor het (haast te goede!) randomiseren en het klaarzetten 
van de vele potjes ‘smurfen-pillen’ voor de doxy-studie. Ook bedankt voor je bijdrage aan 
het analgetica stuk. Leuk dat jij nu mede-auteur bent van een van de artikelen in mijn 
proefschrift, want met mijn mede-auteurschap aan een van jouw artikelen begon mijn 
onderzoeks-carrière!
Jaap Fransen, bedankt voor je uitgebreide bijdrage aan het artikel over vermoeidheid.
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Mijn collega-onderzoekers van ReumaResearch wil ik graag bedanken voor de fijne 
samenwerking, in het bijzonder de andere artrose-onderzoekers Agnes, Mirelle en 
Thomas. Mirelle, dank voor je bijdrage aan het artikel over vermoeidheid en voor de 
gezellig wandelingetjes rond ‘de berg’ tussen de middag. Thomas, dank voor de super 
goede samenwerking voor ons ‘CHECK-stuk’. Je wordt/bent een heel goede onderzoeker. 
Ik kijk uit naar jouw proefschrift! 
Dan wil ik natuurlijk ook de ‘artrose-dokters’ (in het bijzonder Vincent en Marianne) 
van het knie-heupartrose spreekuur bedanken. Zonder jullie hulp had ik nooit zo snel 
zoveel patiënten in de onderzoeken kunnen includeren. Vincent, mooi om te zien dat 
de patiënten ‘met je weglopen’. Elien, de nieuwste artrose-dokter, succes met jouw 
proefschrift. Ik had me geen betere opvolgster kunnen wensen.
Orthopedisch chirurgen van het Orthopediecentrum, bedankt voor het verwijzen van 
zoveel patiënten. Harald de Man en Koen Defoort, jullie waren mijn ‘hofleveranciers’, 
bedankt!
Mijn dank gaat uit naar jou, Susan (secretariaat), voor al je hulp met powerpoint, het 
maken van brieven, het uitprinten van het manuscript en nog veel meer. Bedankt voor 
de fijne samenwerking. Ook bedank ik hierbij de andere medewerkers op het secretariaat 
voor hulp en gezelligheid. Daarnaast bedank ik Brigitte en Susan (polikliniek) voor de 
planning van de knieartrose patiënten van de doxy-studie, dit was vaak een hels karwei. 
Medewerkers van de polikliniek Reumatologie, bedankt voor de fijne samenwerking. 
Datamanagers, Freek, Nathalie en Nathan dank voor jullie invoerwerk! Dr. Dirk-Jan de 
Rooij, dank voor het scoren van de vele röntgenfoto's.
Karen, mijn kamergenoot, ik ben heel blij met onze vriendschap die in de afgelopen 
jaren ontstaan is. Deze is me heel dierbaar. Fijn dat we lief en leed met elkaar konden 
delen. 
Victor, wat heerlijk dat wij elkaar opnieuw gevonden hebben! Bedankt voor de goede 
gesprekken onder het genot van een triple-tje; er zullen er zeker nog velen volgen. Super 
dat je mijn paranimf bent! 
Aatke, dank voor alle koppen zwarte koffie die wij als ‘koffie-die-hards’ met elkaar 
deelden. Ook dank voor de gezellige avonden; we blijven elkaar zeker zien. Leuk dat je 
mijn paranimf wilt zijn! Jouw boekje komt vast ook snel af!
Jongens van Uni v.v. dank voor de heerlijke voetbalpartijen, slechte en goede 
wedstrijden, stapavonden, verhuizingen, ik had het niet willen missen. Het ‘Uni v.v.-
gevoel’ is uniek en voetbal is de belangrijkste bijzaak!
Beste B&J, dank voor alle gezellige avondjes rikken en dat we onze onderzoeksperikelen 
met elkaar konden delen.
Beste familie, lieve mama, papa, Koen, Freek en Els, dank voor jullie steun en 
vertrouwen.
Tot slot mijn Michelle, Liefie, jou ben ik de meeste dank verschuldigd. Ongelooflijk hoe 
jij me steeds weer op weg hielp als ik het allemaal weer eens niet overzag. Zonder jouw 
praktische adviezen was dit proefschrift nog lang niet af. Je bent de eerste dermatoloog 
die alles van artrose weet, haha! Daarnaast dank voor je liefde en vertrouwen in mij. 
Hopelijk krijgen we nu wat meer rust en tijd om te genieten van ons leven samen. Two 
down!
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